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reamble
he medical profession should play a central role in evalu-
ing the evidence related to drugs, devices, and procedures
r the detection, management, and prevention of disease.
hen properly applied, expert analysis of available data on
e benefits and risks of these therapies and procedures can
prove the quality of care, optimize patient outcomes, and
vorably affect costs by focusing resources on the most
fective strategies. An organized and directed approach to a
orough review of evidence has resulted in the production of
inical practice guidelines that assist physicians in selecting
e best management strategy for an individual patient.
oreover, clinical practice guidelines can provide a founda-
on for other applications, such as performance measures,
propriate use criteria, and both quality improvement and
inical decision support tools.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly
oduced guidelines in the area of cardiovascular disease
nce 1980. The ACCF/AHA Task Force on Practice Guide-
nes (Task Force), charged with developing, updating, and
vising practice guidelines for cardiovascular diseases and
ocedures, directs and oversees this effort. Writing commit-
es are charged with regularly reviewing and evaluating all
ailable evidence to develop balanced, patient-centric rec-
mendations for clinical practice.
Experts in the subject under consideration are selected by
e ACCF and AHA to examine subject-specific data and
rite guidelines in partnership with representatives from
her medical organizations and specialty groups. Writing
mmittees are asked to perform a formal literature review;
eigh the strength of evidence for or against particular tests,
eatments, or procedures; and include estimates of expected
tcomes where such data exist. Patient-specific modifiers,
morbidities, and issues of patient preference that may
fluence the choice of tests or therapies are considered.
hen available, information from studies on cost is consid-
ed, but data on efficacy and outcomes constitute the primary
sis for the recommendations contained herein.
In analyzing the data and developing recommendations and
pporting text, the writing committee uses evidence-based
ethodologies developed by the Task Force (1). The Class of
ecommendation (COR) is an estimate of the size of the
eatment effect considering risks versus benefits in addition
evidence and/or agreement that a given treatment or
ocedure is or is not useful/effective or in some situations
ay cause harm. The Level of Evidence (LOE) is an estimate
the certainty or precision of the treatment effect. The
riting committee reviews and ranks evidence supporting
ch recommendation with the weight of evidence ranked asOE A, B, or C according to specific definitions that are
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trospective, prospective, or randomized where appropriate.
or certain conditions for which inadequate data are avail-
le, recommendations are based on expert consensus and
inical experience and are ranked as LOE C. When recom-
endations at LOE C are supported by historical clinical
ta, appropriate references (including clinical reviews) are
ted if available. For issues for which sparse data are
ailable, a survey of current practice among the members of
e writing committee is the basis for LOE C recommenda-
ons and no references are cited. The schema for COR and
OE is summarized in Table 1, which also provides sug-
sted phrases for writing recommendations within each
ble 1. Applying Classification of Recommendation and Level o
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.OR. AA new addition to this methodology is separation of the
lass III recommendations to delineate whether the recom-
endation is determined to be of “no benefit” or is associated
ith “harm” to the patient. In addition, in view of the
creasing number of comparative effectiveness studies, com-
rator verbs and suggested phrases for writing recommen-
tions for the comparative effectiveness of one treatment or
rategy versus another are included for COR I and IIa, LOE
or B only.
In view of the advances in medical therapy across the
ectrum of cardiovascular diseases, the Task Force has
signated the term guideline-directed medical therapy
DMT) to represent optimal medical therapy as defined by
nce
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involvef Evide
mmend
ble, the
in diffe
dence ACCF/AHA guideline-recommended therapies (primarily
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bsequent guidelines.
Because the ACCF/AHA practice guidelines address pa-
ent populations (and healthcare providers) residing in North
merica, drugs that are not currently available in North
merica are discussed in the text without a specific COR. For
udies performed in large numbers of subjects outside North
merica, each writing committee reviews the potential influ-
ce of different practice patterns and patient populations on
e treatment effect and relevance to the ACCF/AHA target
pulation to determine whether the findings should inform a
ecific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches to the diag-
sis, management, and prevention of specific diseases or
nditions. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
made by the healthcare provider and patient in light of all
e circumstances presented by that patient. As a result,
tuations may arise for which deviations from these guide-
nes may be appropriate. Clinical decision making should
volve consideration of the quality and availability of
pertise in the area where care is provided. When these
idelines are used as the basis for regulatory or payer
cisions, the goal should be improvement in quality of
re. The Task Force recognizes that situations arise in
hich additional data are needed to inform patient care
ore effectively; these areas are identified within each
spective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if followed. Because lack
patient understanding and adherence may adversely affect
tcomes, physicians and other healthcare providers should
ake every effort to engage the patient’s active participation
prescribed medical regimens and lifestyles. In addition,
tients should be informed of the risks, benefits, and
ternatives to a particular treatment and should be involved
shared decision making whenever feasible, particularly for
OR IIa and IIb, for which the benefit-to-risk ratio may be
wer.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
relationships with industry and other entities (RWI) among
e members of the writing committee. All writing committee
embers and peer reviewers of the guideline are required to
sclose all current healthcare related relationships, including
ose existing 12 months before initiation of the writing
fort. In December 2009, the ACCF and AHA implemented
new RWI policy that requires the writing committee chair
us a minimum of 50% of the writing committee to have no
levant RWI. (Appendix 1 includes the ACCF/AHA defini-
on of relevance.) These statements are reviewed by the Task
orce and all members during each conference call and/or
eeting of the writing committee, and members provide
dates as changes occur. All guideline recommendations
quire a confidential vote by the writing committee and must
approved by a consensus of the voting members. Members caay not draft or vote on any text or recommendations
rtaining to their RWI. Members who recused themselves
om voting are indicated in the list of writing committee
embers, and specific section recusals are noted in Appendix
Authors’ and peer reviewers’ RWI pertinent to this
ideline are disclosed in Appendixes 1 and 2, respectively.
addition, to ensure complete transparency, writing com-
ittee members’ comprehensive disclosure information—
cluding RWI not pertinent to this document—is available as
online supplement. Comprehensive disclosure information
r the Task Force is also available online at http://www.
rdiosource.org/ACC/About-ACC/Who-We-Are/Leadership/
uidelines-and-Documents-Task-Forces.aspx. The work of
riting committees is supported exclusively by the ACCF and
HA without commercial support. Writing committee members
lunteered their time for this activity.
In an effort to maintain relevance at the point of care for
acticing physicians, the Task Force continues to oversee an
going process improvement initiative. As a result, in
sponse to pilot projects, several changes to these guidelines
ill be apparent, including limited narrative text, a focus on
mmary and evidence tables (with references linked to
stracts in PubMed), and more liberal use of summary
commendation tables (with references that support LOE) to
rve as a quick reference.
In April 2011, the Institute of Medicine released 2 reports:
inding What Works in Health Care: Standards for System-
ic Reviews and Clinical Practice Guidelines We Can Trust
,3). It is noteworthy that the IOM cited ACCF/AHA
actice guidelines as being compliant with many of the
oposed standards. A thorough review of these reports and
our current methodology is under way, with further
hancements anticipated.
The recommendations in this guideline are considered
rrent until they are superseded by a focused update or the
ll-text guideline is revised. Guidelines are official policy of
th the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he recommendations listed in this document are, whenever
ssible, evidence based. The current document constitutes a
ll revision and includes an extensive evidence review,
hich was conducted through November 2010, with addi-
onal selected references added through August 2012.
earches were limited to studies conducted in human subjects
d reviews and other evidence pertaining to human subjects;
l were published in English. Key search words included but
ere not limited to: acute coronary syndromes, percutaneous
ronary intervention, coronary artery bypass graft, myocar-
al infarction, ST-elevation myocardial infarction, coronary
ent, revascularization, anticoagulant therapy, antiplatelet
erapy, antithrombotic therapy, glycoprotein IIb/IIIa inhibitor
erapy, pharmacotherapy, proton-pump inhibitor, implantable
rdioverter-defibrillator therapy, cardiogenic shock, fibrino-
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ications, arrhythmia, angina, chronic stable angina, diabetes,
ronic kidney disease, mortality, morbidity, elderly, ethics,
d contrast nephropathy. Additional searches cross-
ferenced these topics with the following subtopics: percu-
neous coronary intervention, coronary artery bypass graft,
rdiac rehabilitation, and secondary prevention. Addition-
ly, the committee reviewed documents related to the subject
atter previously published by the ACCF and AHA. Refer-
ces selected and published in this document are represen-
tive and not all-inclusive.
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published, the abso-
te risk difference and number needed to treat or harm are
ovided in the guideline, along with confidence intervals
I) and data related to the relative treatment effects such as
ds ratio (OR), relative risk (RR), hazard ratio (HR), or
cidence rate ratio.
The focus of this guideline is the management of patients
ith ST-elevation myocardial infarction (STEMI). Updates to
e 2004 STEMI guideline were published in 2007 and 2009
–6). Particular emphasis is placed on advances in reperfu-
on therapy, organization of regional systems of care, trans-
r algorithms, evidence-based antithrombotic and medical
erapies, and secondary prevention strategies to optimize
tient-centered care. By design, the document is narrower in
ope than the 2004 STEMI Guideline, in an attempt to
ovide a more focused tool for practitioners. References
lated to management guidelines are provided whenever
propriate, including those pertaining to percutaneous cor-
ary intervention (PCI), coronary artery bypass graft
ABG), heart failure (HF), cardiac devices, and secondary
evention.
.2. Organization of the Writing Committee
he writing committee was composed of experts representing
rdiovascular medicine, interventional cardiology, electro-
ysiology, HF, cardiac surgery, emergency medicine, inter-
l medicine, cardiac rehabilitation, nursing, and pharmacy.
he American College of Physicians, American College of
mergency Physicians, and Society for Cardiovascular An-
ography and Interventions assigned official representatives.
.3. Document Review and Approval
his document was reviewed by 2 outside reviewers each
minated by the ACCF and the AHA, as well as 2 reviewers
ch from the American College of Emergency Physicians
d Society for Cardiovascular Angiography and Interven-
ons and 22 individual content reviewers (including members
om the ACCF Interventional Scientific Council and ACCF
urgeons’ Scientific Council). All reviewer RWI information
as distributed to the writing committee and is published in
is document (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and was endorsed
the American College of Emergency Physicians and
ociety for Cardiovascular Angiography and Interventions. M. Background
.1. Definition and Diagnosis
TEMI is a clinical syndrome defined by characteristic
mptoms of myocardial ischemia in association with persis-
nt electrocardiographic (ECG) ST elevation and subsequent
lease of biomarkers of myocardial necrosis. Diagnostic ST
evation in the absence of left ventricular (LV) hypertrophy
left bundle-branch block (LBBB) is defined by the Euro-
an Society of Cardiology/ACCF/AHA/World Heart Feder-
ion Task Force for the Universal Definition of Myocardial
farction as new ST elevation at the J point in at least 2
ntiguous leads of 2 mm (0.2 mV) in men or 1.5 mm
.15 mV) in women in leads V2–V3 and/or of 1 mm (0.1
V) in other contiguous chest leads or the limb leads (7). The
ajority of patients will evolve ECG evidence of Q-wave
farction. New or presumably new LBBB has been consid-
ed a STEMI equivalent. Most cases of LBBB at time of
esentation, however, are “not known to be old” because of
ior electrocardiogram (ECG) is not available for compari-
n. New or presumably new LBBB at presentation occurs
frequently, may interfere with ST-elevation analysis, and
ould not be considered diagnostic of acute myocardial
farction (MI) in isolation (8). Criteria for ECG diagnosis of
ute STEMI in the setting of LBBB have been proposed (see
nline Data Supplement 1). Baseline ECG abnormalities
her than LBBB (e.g., paced rhythm, LV hypertrophy,
rugada syndrome) may obscure interpretation. In addition,
T depression in 2 precordial leads (V1–V4) may indicate
ansmural posterior injury; multilead ST depression with
existent ST elevation in lead aVR has been described in
tients with left main or proximal left anterior descending
tery occlusion (9). Rarely, hyperacute T-wave changes may
observed in the very early phase of STEMI, before the
velopment of ST elevation. Transthoracic echocardiogra-
y may provide evidence of focal wall motion abnormalities
d facilitate triage in patients with ECG findings that are
fficult to interpret. If doubt persists, immediate referral for
vasive angiography may be necessary to guide therapy in
e appropriate clinical context (10,11). Cardiac troponin is
e preferred biomarker for diagnosis of MI.
.2. Epidemiology
2009, approximately 683,000 patients were discharged
om U.S. hospitals with a diagnosis of acute coronary
ndrome (ACS). Community incidence rates for STEMI
ve declined over the past decade, whereas those for
n–ST-elevation ACS have increased (Figure 1). At present,
TEMI comprises approximately 25% to 40% of MI presen-
tions (12–15). In-hospital (approximately 5% to 6%) and
year (approximately 7% to 18%) mortality rates from
TEMI also have decreased significantly in association with
substantial increase in the frequency of care that includes
DMT and interventions (“defect-free” care) (13,15–18). In
e United States, important regional differences exist in
-day acute MI hospital mortality and readmission rates for
edicare beneficiaries 65 years of age (19). Understanding
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rformance improvement (20).
Approximately 30% of patients with STEMI are women.
emale sex was a strong independent predictor of failure to
ceive reperfusion therapy among patients who had no
ntraindications in the CRUSADE (Can Rapid Risk Strati-
cation of Unstable Angina Patients Suppress Adverse Out-
mes with Early Implementation of the ACC/AHA Guide-
nes) registry (21). Compared with men, women included in
e NCDR (National Cardiovascular Data Registry) ACTION
egistry–GWTG (Get With The Guidelines) presented later
ter symptom onset, had longer door-to-fibrinolysis and
or-to-balloon (or device) (D2B) times, and less often
ceived aspirin or beta blockers within 24 hours of presen-
tion. Women further were characterized by a higher risk for
eeding with antithrombotic therapy, which persisted after
nsideration of age, weight, blood pressure (BP) at presen-
tion, renal function, baseline hematocrit, and other potential
nfounders (22).
Nonwhites represented 13.3% of patients with STEMI at
spitals participating in the ACTION Registry–GWTG in
arters 1 and 2 of 2009 (17). Importantly, disparities in the
eatment of racial and ethnic minorities appear to be improv-
g over time (23). In an assessment of the effects of a
atewide program for treatment of STEMI, institution of a
ordinated regional approach to triage and management was
sociated with significant improvements in treatment times
at were similar for whites and blacks and for women and
en (23). The writing committee endorses the desirability of
llecting and using accurate data on patient race and
hnicity to detect disparities, guide quality improvement
itiatives, and strengthen ties to the community (24).
Approximately 23% of patients with STEMI in the United
tates have diabetes mellitus (17), and three quarters of all
aths among patients with diabetes mellitus are related to
ronary artery disease (25,26). Diabetes mellitus is associ-
ed with higher short- and long-term mortality after STEMI
7,28), and in patients with diabetes mellitus, both hyper-
ycemia and hypoglycemia are associated with worse out-
mes (29). Hyperglycemia at presentation in patients who do
t have diabetes mellitus by history has been associated with
orse hospital outcomes (30–34). Myocardial tissue perfu-
on after restoration of epicardial coronary flow was more
gure 1. Age- and sex-adjusted incidence rates of acute MI,
99 to 2008. I bars represent 95% confidence intervals. MI in-
cates myocardial infarction; STEMI, ST-elevation myocardial
farction. Reprinted with permission from Yeh et al. (14).paired among patients with diabetes mellitus (“no-reflow”) m8,35,36). Management of patients with diabetes mellitus
d STEMI should be the same as for patients without
abetes mellitus, with attention to moderate glycemic
ntrol.
The elderly comprise a growing segment of the population
d present special challenges for diagnosis and management
at may lead to disparities in care and delays in treatment.
dditional issues to consider include the risks of antithrom-
tic and interventional therapies and the appropriate bound-
ies of care within the context of individual comorbidities,
ailty, and advanced-care directives. Clinical trials fre-
ently have limited enrollment of older populations (37).
reatments that are effective in younger populations usually
e indicated in the elderly, with the caveat that the elderly
ore often have absolute or relative contraindications to their
e. Impaired renal function associated with aging requires
reful attention to drug dosing (38,39).
In an analysis of 8,578 patients with STEMI from 226 U.S.
spitals participating in the CRUSADE quality improve-
ent initiative from September 2004 to December 2006, 7%
eligible patients did not receive reperfusion therapy (21).
he factor most strongly associated with not providing
perfusion therapy in eligible patients was increasing age.
vidence suggests that even the very elderly have reasonable
st-MI outcomes when treated aggressively with reperfusion
erapy (40), though individual circumstances vary.
Both the GWTG Quality Improvement Program and the
orth Carolina Reperfusion of Acute Myocardial Infarction
Carolina Emergency Department’s initiative demonstrated
at focused quality improvement efforts and programs de-
gned to systematize care across integrated regional centers
n lessen disparities and improve the care of elderly patients
ith STEMI (23,41).
Numerous studies have highlighted the fact that patients with
ronic kidney disease of all stages less frequently receive
ideline-recommended interventions than do patients with
rmal renal function, despite evidence of benefit from most
ute treatments (42–45). In a project that linked the U.S. Renal
ata System database with the NRMI (National Registry of
yocardial Infarction)–3, patients on dialysis had longer
ehospital delays, were less often recognized as having an
ute MI, and less often had ST elevation or LBBB on initial
CG than patients not on dialysis. Only 45% of eligible
tients on dialysis received reperfusion therapy, and only
% received aspirin on admission. The in-hospital mortality
te was 21.3% among patients on dialysis, compared with
.7% for patients with end-stage renal failure not on dialy-
s. At discharge, only 67% of patients on dialysis were
escribed aspirin, and only 57% were prescribed beta block-
s. In the GRACE (Global Registry of Acute Coronary
vents) registry, the in-hospital mortality rate was approxi-
ately 30% among patients with STEMI or LBBB MI with
age 4 or 5 chronic kidney disease. Both fibrinolysis and
imary PCI were associated with higher bleeding rates in
tients with severely reduced renal function (46). Progres-
ve renal dysfunction is a strong predictor of bleeding with
tithrombotic therapy, a risk that may reflect intrinsic renal
sfunction and/or failure to adjust or avoid antithrombotic
edications that are dependent on renal elimination (22,47).
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lobal risk assessment provides an opportunity to integrate
rious patient characteristics into a semiquantitative score
at can convey an overall estimate of a patient’s prognosis;
n dictate the acuity, intensity, and location of care; and can
ovide the patient and family with a more informed sense of
tential outcome. Higher risk scores generally imply that
gher-intensity treatments may be appropriate within the
ntext of the patient’s health status.
Some of the independent predictors of early death from
TEMI include age, Killip class, time to reperfusion, cardiac
rest, tachycardia, hypotension, anterior infarct location, prior
farction, diabetes mellitus, smoking status, renal function, and
omarker findings (48,49). Whereas the Thrombolysis In Myo-
rdial Infarction (TIMI) risk score was developed specifically
patients with STEMI (http://www.mdcalc.com/timi-risk-
ore-for-stemi), the GRACE model (http://www.outcomes-
assmed.org/grace/acs_risk/acs_risk_content.html) predicts
-hospital and 6-month mortality rate across the spectrum of
tients presenting with ACS, including those with ST elevation
ST depression. Risk assessment is a continuous process that
ould be repeated throughout hospitalization and at time of
scharge.
. Onset of MI
.1. Patient-Related Delays and Initial
reatment
atients with STEMI do not seek medical care for approxi-
ately 1.5 to 2 hours after symptom onset, and little change
this interval has occurred over the past 10 years (50,51).
atient delay times are often longer in women, blacks, the
derly, and Medicaid-only recipients and are shorter for
edicare recipients (compared with privately insured pa-
ents) and patients who are taken directly to the hospital by
ergency medical services (EMS) transport (52,53). Pa-
ents may delay seeking care because their symptoms differ
om their preexisting bias that a heart attack should present
amatically with severe, crushing chest pain (54). Approxi-
ately one third of patients with MI experience symptoms
her than chest pain (7). Other reasons for delay in seeking
eatment include 1) inappropriate reasoning that symptoms
ill be self-limited or are not serious (55–57); 2) attribution
symptoms to other preexisting conditions; 3) fear of
barrassment should symptoms turn out to be a “false
arm”; 4) reluctance to trouble others unless “really sick”
5,57,58); 5) preconceived stereotypes of who is at risk for
heart attack, an especially common trait among women
9); 6) lack of knowledge of the importance of rapid action,
e benefits of calling EMS or 9-1-1, and the availability of
perfusion therapies (54); and 7) attempted self-treatment
ith prescription and/or nonprescription medications (57). To
oid such delays, healthcare providers should assist patients
hen possible in making anticipatory plans for timely recog-
tion and response to an acute event. Family members, close
iends, or advocates also should be enlisted as reinforcement
r rapid action when the patient experiences symptoms of
ssible STEMI (60,61). Discussions should include a reviewinstructions for taking aspirin (62) and nitroglycerin in
sponse to chest pain. Emergency medical dispatchers are
ained to instruct patients with possible STEMI symptoms to
ew non–enteric-coated aspirin (162 to 325 mg), unless
ntraindicated, while personnel are en route. If nitroglycerin
prescribed, the patient should be advised to take 1 nitro-
ycerin dose promptly. If symptoms are unimproved or
orsening 5 minutes after 1 dose, the patient should be
structed to call 9-1-1 immediately.
.2. Mode of Transport to the Hospital
ven though 98% of the U.S. population is covered by
1-1 service (63), patients with STEMI often do not call
MS or 9-1-1 and are not transported to the hospital by
bulance. In a 2011 observational study from the ACTION
egistry–GWTG that used data reported from a limited
mber of predominantly PCI-capable U.S. hospitals, EMS
ansport was used for only 60% of 37,643 patients with
TEMI (64). Older U.S. surveys reported EMS activation
tes of 23% to 53%, with substantial geographic variability
2,65,66).
Patients with possible ischemic symptoms should be trans-
rted to the hospital by ambulance rather than by friends or
latives because 1) 1 in every 300 patients with chest pain
ansported to the emergency department (ED) by private
hicle suffers cardiac arrest en route (67); and 2) there is a
gnificant association between arrival at the ED by ambu-
nce and earlier delivery of reperfusion therapy (64–66,68).
addition, the performance of prehospital ECGs by trained
rsonnel is associated with shorter reperfusion times (69)
d lower mortality rates from STEMI. The use of prehospital
CGs, particularly when coupled with communication of
TEMI diagnosis and preferential transport to a PCI-capable
spital, has been shown to result in rapid reperfusion times
d excellent clinical outcomes (70–72).
.3. Patient Education
he AHA and National Institutes of Health “Act in Time to
eart Attack Signs” campaign (73) stresses that patients can
crease their chance of surviving STEMI by learning the
arning symptoms, filling out a survival plan, and discussing
sk reduction with their physician. These materials are
ailable on the National Institutes of Health “Heart Attack”
eb page (http://health.nih.gov/topic/HeartAttack/) (74).
ealthcare providers should target their educational interven-
ons to patients at increased risk for ACS (75).
.4. Community Preparedness and System
oals for Reperfusion Therapy
.4.1. Regional Systems of STEMI Care, Reperfusion
herapy, and Time-to-Treatment Goals:
ecommendations
ee Figure 2.
ASS I
All communities should create and maintain a regional system
of STEMI care that includes assessment and continuous qual-
ity improvement of EMS and hospital-based activities. Perfor-
mance can be facilitated by participating in programs such as
2.
3.
4.
5.
6.
7.
8.
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Evidence: B)
Performance of a 12-lead ECG by EMS personnel at the site of
first medical contact (FMC) is recommended in patients with
symptoms consistent with STEMI (70–72,79,80). (Level of
Evidence: B)
Reperfusion therapy should be administered to all eligible
patients with STEMI with symptom onset within the prior 12
hours (81,82). (Level of Evidence: A)
Primary PCI is the recommended method of reperfusion when it
can be performed in a timely fashion by experienced operators
(82–84). (Level of Evidence: A)
EMS transport directly to a PCI-capable hospital for primary
PCI is the recommended triage strategy for patients with
STEMI, with an ideal FMC-to-device time system goal of 90
minutes or less* (70–72). (Level of Evidence: B)
Immediate transfer to a PCI-capable hospital for primary PCI is
the recommended triage strategy for patients with STEMI who
initially arrive at or are transported to a non–PCI-capable
hospital, with an FMC-to-device time system goal of 120
minutes or less* (83–86). (Level of Evidence: B)
he proposed time windows are system goals. For any individual patient, every
gure 2. Reperfusion therapy for patients with STEMI. The bold a
ctated by an anatomically appropriate culprit stenosis. Patients
CI-capable hospital should be transferred for cardiac catheteriz
e delay from MI onset (Class I, LOE: B). †Angiography and re
urs after administration of fibrinolytic therapy. CABG indicate
edical contact; LOE, Level of Evidence; MI, myocardial infarct
T-elevation myocardial infarction.anort should be made to provide reperfusion therapy as rapidly as possible.In the absence of contraindications, fibrinolytic therapy should
be administered to patients with STEMI at non–PCI-capable
hospitals when the anticipated FMC-to-device time at a PCI-
capable hospital exceeds 120 minutes because of unavoidable
delays (81,87,88). (Level of Evidence: B)
When fibrinolytic therapy is indicated or chosen as the primary
reperfusion strategy, it should be administered within 30
minutes of hospital arrival* (89–93). (Level of Evidence: B)
ASS IIa
Reperfusion therapy is reasonable for patients with STEMI and
symptom onset within the prior 12 to 24 hours who have
clinical and/or ECG evidence of ongoing ischemia. Primary PCI
is the preferred strategy in this population (81,94,95). (Level
of Evidence: B)
.4.1.1. REGIONAL SYSTEMS OF STEMI CARE AND GOALS
R REPERFUSION THERAPY
ny regional medical system must seek to enable rapid
cognition and timely reperfusion of patients with STEMI.
ystem delays to reperfusion are correlated with higher rates
mortality and morbidity (96–100). Although attention to
rtain performance metrics, such as D2B, door-to-needle,
and boxes are the preferred strategies. Performance of PCI is
ardiogenic shock or severe heart failure initially seen at a non–
nd revascularization as soon as possible, irrespective of
larization should not be performed within the first 2 to 3
nary artery bypass graft; DIDO, door-in–door-out; FMC, first
I, percutaneous coronary intervention; and STEMI,rrows
with c
ation a
vascu
s coro
ion; PCd door-in–door-out times, have catalyzed important insti-
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January 29, 2013:e78–140 2013 ACCF/AHA STEMI Guideline: Full Texttional quality improvement efforts, broader initiatives at a
stems level are required to reduce total ischemic time, the
incipal determinant of outcome (101,102). Questions have
en raised about the overreliance on primary PCI for
perfusion, especially in the United States, and the unin-
nded consequences that have evolved as familiarity with
brinolysis has waned (101). The writing committee reiter-
es the principle highlighted in the 2004 ACC/AHA STEMI
ideline, namely that “the appropriate and timely use of
me form of reperfusion therapy is likely more important
an the choice of therapy” (4). Greatest emphasis is to be
aced on the delivery of reperfusion therapy to the individual
tient as rapidly as possible.
Only a minority of U.S. hospitals are capable of perform-
g primary PCI (103), and any delay in time to reperfusion
2B) after hospital arrival is associated with a higher
justed risk of in-hospital mortality in a continuous, nonlin-
r fashion (96). Strict time goals for reperfusion may not
ways be relevant or possible for patients who have an
propriate reason for delay, including initial uncertainty
out diagnosis, the need for evaluation and treatment of
her life-threatening conditions (e.g., acute respiratory fail-
e, cardiac arrest), delays involving informed consent, and
ng transport times due to geographic distance or adverse
eather. To reduce hospital treatment delays, the ACC
itiated the D2B Alliance in 2006 to improve door-to-device
mes in patients with STEMI (104). The D2B Alliance goal
as for participating PCI-capable hospitals to achieve a D2B
e of 90 minutes for at least 75% of nontransferred patients
ith STEMI. The Alliance met this goal by 2008 (105). A
ngitudinal study of hospitals participating in the NCDR Cath-
CI Registry demonstrated that patients treated in hospitals that
d been enrolled in the D2B Alliance for 3 months were
gnificantly more likely to have D2B times of 90 minutes than
tients treated in nonenrolled hospitals (105).
In a similar manner, the AHA launched “Mission: Life-
ne” in 2007 to improve health system readiness and re-
onse to STEMI (106,107), with a focus on the continuum of
re from EMS activation to primary PCI. Patients may
esent directly by private transport to a PCI-capable hospital,
which case all medical care occurs in a single center
sponsible for optimizing door-to-device times. For patients
ho call 9-1-1, direct care begins with FMC, defined as the
me at which the EMS provider arrives at the patient’s side.
MS personnel should be accountable for obtaining a pre-
spital ECG, making the diagnosis, activating the system,
d deciding whether to transport the patient to a PCI-capable
non–PCI-capable hospital. Consideration should be given
the development of local protocols that allow preregistra-
on and direct transport to the catheterization laboratory of a
CI-capable hospital (bypassing the ED) for patients who do
t require emergent stabilization upon arrival. Although
alse positives” are a concern when EMS personnel and/or
ergency physicians are allowed to activate the cardiac
theterization laboratory, the rate of false activations is
latively low (approximately 15%) and is more than bal-
ced by earlier treatment times for the majority of patients
r whom notification is appropriate (108–114). The concept prwhat constitutes false activation is evolving (115,116). For
tients who arrive at or are transported by EMS to a
n–PCI-capable hospital, a decision about whether to trans-
r immediately to a PCI-capable hospital or to administer
brinolytic therapy must be made. Each of these scenarios
volves coordination of different elements of the system. On
e basis of model systems of STEMI care in the United
tates and Europe, (77,78,117–121) Mission: Lifeline recom-
ends a multifaceted community-wide approach that involves
tient education, improvements in EMS and ED care, estab-
hment of networks of STEMI-referral (non–PCI-capable) and
TEMI-receiving (PCI-capable) hospitals, and coordinated ad-
cacy efforts to work with payers and policy makers to imple-
ent healthcare system redesign. Detailed information about this
ogram can be found on the AHA website (122).
Several factors should be considered in selecting the type
reperfusion therapy (Figure 2). For patients with STEMI
esenting to a PCI-capable hospital, primary PCI should be
complished within 90 minutes. For patients presenting to a
n–PCI-capable hospital, rapid assessment of 1) the time
om onset of symptoms, 2) the risk of complications related
STEMI, 3) the risk of bleeding with fibrinolysis, 4) the
esence of shock or severe HF, and 5) the time required for
ansfer to a PCI-capable hospital must be made and a
cision about administration of fibrinolytic therapy reached.
ven when interhospital transfer times are short, there may be
lative advantages to a strategy of immediate fibrinolytic
erapy versus any delay to primary PCI for eligible patients
ho present within the first 1 to 2 hours after symptom onset
9,101,123,124).
Several trials have suggested a benefit of transferring
tients with STEMI from a non–PCI-capable hospital to a
CI-capable hospital for primary PCI (83,125), but in many
stances, transfer times are prolonged and delays may be
avoidable. In the NCDR (126,127), only 10% of trans-
rred patients were treated within 90 minutes of initial
esentation, with a median first door-to-device time of 149
inutes. In many communities, a significant percentage of
tients with STEMI who present initially to a non–PCI-
pable hospital cannot physically be transferred to a PCI-
pable hospital and achieve an FMC-to-device time treat-
ent goal of 90 minutes. DANAMI-2 (Danish Multicenter
andomized Study on Thrombolytic Therapy Versus Acute
oronary Angioplasty in Acute Myocardial Infarction)
owed that a reperfusion strategy involving the transfer of
tients with STEMI from a non–PCI-capable hospital to a
CI-capable hospital for primary PCI was superior to the use
fibrinolysis at the referring hospital, driven primarily by a
duction in the rate of reinfarction in the primary PCI–
eated group (83,85). In this study, the average first door-to-
vice time delay was approximately 110 minutes (85).
horter system delays were associated with a reduced mor-
lity rate for both fibrinolysis- and primary PCI–treated
tients. In an analysis of approximately 19,000 propensity
ore–matched patients with STEMI from NRMI-2, -3, -4,
d -5, when delays related to transfer for primary PCI
ceeded 120 minutes from FMC, the survival advantage of
imary PCI over fibrinolysis was negated. Delays beyond
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alysis (100). Thus, interhospital transfer to a PCI-capable
spital is the recommended triage strategy if primary PCI
nsistently can be performed within 120 minutes of FMC.
ibrinolytic therapy, in the absence of contraindications to its
e, should be administered within 30 minutes of first door
rival when this 120-minute time goal cannot be met.
ransfer delays can occur at multiple levels and for varied
asons (128). Efforts are needed to reduce the time delay
tween arrival to and transfer from a non–PCI-capable
spital (i.e., door-in–door-out). Among a subset of 14,821
tients in the NCDR ACTION–GWTG registry, the median
or-in–door-out time was 68 minutes (interquartile range,
to 120 minutes). A door-in–door-out time 30 minutes,
hieved in only 11% of patients, was associated with shorter
lays to reperfusion and a lower in-hospital mortality rate
29). Because estimation of treatment times for patients can
inaccurate, the decision to transfer for primary PCI should
based on actual, historical times achieved within the
gional system, with quality assurance programs to ensure
at such goals are consistently met. A reasonable goal would
that 90% of patients should meet the 120-minute time-to-
eatment standard to achieve performance standards.
Several triage and transfer strategies have been tested and
e discussed further in Section 5.3. The term facilitated PCI
as used previously to describe a strategy of full- or half-dose
brinolysis, with or without administration of a glycoprotein
P) IIb/IIIa receptor antagonist, with immediate transfer for
anned PCI within 90 to 120 minutes. Two large studies
iled to show a net clinical benefit with this strategy
30,131). The term rescue PCI refers to the transfer for PCI
patients who demonstrate findings of failed reperfusion
ith fibrinolysis (103,130). The term pharmacoinvasive
rategy refers to the administration of fibrinolytic therapy
ther in the prehospital setting or at a non–PCI-capable
spital, followed by immediate transfer to a PCI-capable
spital for early coronary angiography and PCI when
propriate. Patients with STEMI who are best suited for
mediate interhospital transfer for primary PCI without
brinolysis are those patients who present with shock or other
gh-risk features, those with high bleeding risk with fibrino-
tic therapy, and those who present 3 to 4 hours after
mptom onset and who have short transfer times. Patients
st suited for initial fibrinolytic therapy are those with low
eeding risk who present very early after symptom onset
2 to 3 hours) to a non–PCI-capable hospital and who have
nger delay to PCI.
Because patients with STEMI may first present with cardiac
rest, regional systems also should emphasize early access to
re (recognition of the problem and bystander activation of
MS), rapid dispatch, bystander cardiopulmonary resuscitation
PR), defibrillation when indicated, advanced cardiac life
pport, and an organized approach to postresuscitation care. In
dition, family members of patients who have had STEMI or
her manifestations of coronary artery disease should be re-
rred to CPR training programs that have a social support
mponent and can familiarize them with the use of automated
ternal defibrillators. S.4.1.2. STRATEGIES FOR SHORTENING DOOR-TO-DEVICE
IMES
he D2B time interval includes 3 key components: door-to-
CG time, ECG–to–catheterization laboratory time, and labora-
ry arrival–to–device time (132). All 3 intervals are dependent on
stem factors that may vary across institutions (132).
Public reporting and national initiatives have focused
uch attention on D2B times (104,133) and the many reasons
r system delays (134). Studies have shown marked differ-
ces in the timeliness of primary PCI across hospitals.
ocusing on the processes of care at the top-performing
stitutions, research has revealed characteristics of institu-
ons associated with exemplary performance (124). Top
spitals have specific cultural attributes that include 1) a
mmitment to an explicit goal of improving D2B times that is
otivated by internal and external pressures, including senior
anagement support; 2) innovative protocols; 3) flexibility in
fining standardized protocols; 4) uncompromising individual
inical leaders; 5) collaborative teams; 6) data feedback to
onitor progress, identify problems, and successes; and 7) an
ganizational culture that fosters resilience to challenges or
tbacks to improvement efforts (135). In addition, several key
ocesses are associated strongly with more timely treatment
hecklist). Other studies have indicated that PCI-capable hos-
tals receiving patients in transfer can reduce their D2B times
coordinating with the referring hospitals and activating their
stems while patients are being transported (78).
Currently, it is estimated that almost 90% of patients
esenting to a hospital with PCI capability and without a
inical reason for delay have a D2B time90 minutes (136).
ome innovative programs are achieving much faster times
37–139). In addition, with improvements in timeliness of
re across the country, racial disparities in reperfusion times
ve been reduced significantly (140). In an analysis of
tients with STEMI reported by hospitals to the Centers for
edicare & Medicaid Services, median D2B times fell from
minutes in the year ending December 31, 2005, to 64
inutes in the 3 quarters ending September 30, 2010. This
cline was accompanied by an increase in the percentage of
tients with D2B times 90 minutes, from 44.2% to 91.4%
41). Nevertheless, despite substantial improvements in
2B times, evidence that these efforts have translated into
duced mortality rates is lacking. The absence of demon-
rated benefit may relate to reduced power to show change in
rvival in a population with a relatively low mortality rate,
proved early survival of higher-risk patients, and changing
ecklist. Improving Door-to-Device Times
Prehospital ECG to diagnose STEMI is used to activate the PCI team while
the patient is en route to the hospital.
Emergency physicians activate the PCI team.
A single call to a central page operator activates the PCI team.
Goal is set for the PCI team to arrive in the catheterization laboratory
within 20 minutes after being paged.
Timely data feedback and analysis are provided to members of the
STEMI care team.TEMI demographics. These findings support the goal of
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improve survival rates.
.5. Prehospital Fibrinolytic Therapy
he time delay from symptom onset to treatment can be
ortened by administration of prehospital fibrinolytic ther-
y by a trained EMS unit either with a physician on board
42–147) or with a hospital-based physician (148–152) in
rect contact, especially in rural areas. Multiple randomized
ntrolled trials (RCTs) have demonstrated the safety and
asibility of prehospital fibrinolytic therapy, with decreased
eatment times ranging from 30 to 140 minutes (142,143,
5–147,149–151,153). A meta-analysis of 6 higher-quality
CTs revealed an approximately 60-minute reduction in time
om symptom onset to delivery of fibrinolytic therapy with
ehospital versus hospital-based administration, with a cor-
sponding 17% reduction in risk of all-cause hospital mor-
lity (154). Analysis of a subgroup of patients enrolled in the
APTIM (Comparaison de l’Angioplastie Primaire et de la
hrombolyse) trial within 2 hours of symptom onset showed
significantly lower 5-year mortality rate for patients treated
ith prehospital fibrinolysis than for patients managed with
imary PCI (p0.04) (123,142). These salutary results for
rly presenters were confirmed in a subsequent analysis of
mbined data from the CAPTIM and WEST (Which Early
T-Elevation Myocardial Infarction Therapy) trials (155).
ata from the USIC (Unité de Soins Intensifs Coronaires)
egistry and the Swedish Registry of Cardiac Intensive Care
so suggest that prehospital fibrinolytic therapy may lower
TEMI mortality rates (144,148).
At the present time, however, prehospital fibrinolytic
erapy is not used in most communities in the United States.
MS in rural areas, where prehospital fibrinolysis would
tentially be of benefit, often have neither the resources to train
ramedics nor the funding for necessary equipment. Use of
ehospital fibrinolysis is more widespread in some regions of
urope and the United Kingdom. The writing committee en-
rses the need for further research into the implementation of
ehospital strategies to reduce total ischemic time.
.6. The Relationship Between
udden Cardiac Death and STEMI
.6.1. Evaluation and Management of Patients With
TEMI and Out-of-Hospital Cardiac Arrest:
ecommendations
ASS I
Therapeutic hypothermia should be started as soon as possible
in comatose patients with STEMI and out-of-hospital cardiac
arrest caused by ventricular fibrillation (VF) or pulseless ven-
tricular tachycardia (VT), including patients who undergo pri-
mary PCI (156–158). (Level of Evidence: B)
Immediate angiography and PCI when indicated should be
performed in resuscitated out-of-hospital cardiac arrest pa-
tients whose initial ECG shows STEMI (159–174). (Level of
Evidence: B)
ee Online Data Supplement 2 for additional data on PCI for
rdiac arrest. caAlmost 70% of the coronary heart disease deaths annually
the United States occur out of hospital, usually presenting
“sudden death” due to cardiac arrest (175). Resuscitation is
tempted by EMS personnel in approximately 60% of these
t-of-hospital cardiac arrest cases; the remaining patients are
ceased on arrival of the EMS team (175–177). Although
ly 23% of out-of-hospital cardiac arrest cases have a
ockable initial rhythm (primarily VF), the majority of
urologically intact survivors come from this subgroup
75,176). The median rate of survival to hospital discharge
ith any first recorded rhythm is only 7.9% (175); the rate of
rvival in patients who are in VF initially is much higher
edian 22%, range 8% to 40%), as documented in 10 U.S.
d Canadian regions participating in the National Institutes
Health–sponsored Resuscitation Outcomes Consortium
76).
Survival from out-of-hospital cardiac arrest is optimal
hen both CPR and defibrillation are initiated early (178).
urvival from VF specifically is inversely related to the time
terval between its onset and termination, with the odds of
rvival decreasing 7% to 10% for each minute of delay from
set to defibrillation (178–180). The percentage of patients
ho are found in VF and the likelihood of survival are higher
the patient’s collapse is witnessed, if bystander CPR is
rformed, and if a monitor/defibrillator can be applied
ickly (181).
Community strategies that improve the delivery of early
fibrillation to out-of-hospital cardiac arrest victims include
aining and equipping first responders (fire and law enforce-
ent), EMS personnel, and paramedics to defibrillate, as well
placing automated external defibrillators in highly popu-
ted locations such as airports, commercial aircraft, and
mbling casinos (“public access defibrillation”) (182–193).
he latter strategy has been shown to approximately double
e number of neurologically intact out-of-hospital cardiac
rest survivors when laypersons are trained and equipped to
ovide early CPR and defibrillation with automated external
fibrillators, compared with providing CPR alone while
aiting arrival of EMS personnel (183).
Two RCTs have reported improved rates of neurologically
tact survival to hospital discharge when comatose patients
ith out-of-hospital VF or nonperfusing VT cardiac arrest
ere cooled to 32°C to 34°C for 12 or 24 hours beginning
inutes to hours after the return of spontaneous circulation
57,158). Additional studies with historical control groups
so have shown improved neurological outcomes after ther-
eutic hypothermia for comatose survivors of VF arrest
94,195). Accordingly, therapeutic hypothermia should be
itiated in patients with STEMI and out-of-hospital cardiac
rest. Cooling should begin before or at the time of cardiac
theterization.
Approximately 5% of patients with STEMI who survive to
ach the hospital will experience a cardiac arrest during
spitalization (196). Reports from high-volume PCI centers
dicate that 4% to 11% of patients with STEMI who are
eated with PCI are brought to cardiac catheterization after
ing resuscitated from out-of-hospital cardiac arrest
7,197,198). However, the percentage of out-of-hospital
rdiac arrest victims whose event is triggered by an acute
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spital cardiac arrest patients who cannot be resuscitated
ve significant coronary atherosclerosis (199). Coronary
herosclerosis is also present in the majority of cardiac arrest
ctims who survive and undergo coronary angiography
00). Because of the high prevalence of acute coronary
tery occlusions in out-of-hospital cardiac arrest patients
ho are resuscitated successfully, especially those whose
itial rhythm is VF in the setting of STEMI, the AHA 2010
uidelines for Cardiopulmonary Resuscitation and Emer-
ncy Cardiovascular Care (201) recommend emergency
ronary angiography with prompt opening of the infarct
tery. Out-of-hospital cardiac arrest victims with initial VF
ho survive to hospital admission have a rate of survival to
spital discharge of 60% after early PCI.
The AHA issued a policy statement calling for communi-
es to establish regional systems of care for out-of-hospital
rdiac arrest (159). The statement defines 2 different levels
cardiac resuscitation centers and lists the essential ele-
ents of such a system. PCI-capable hospitals become ideal
ndidates to serve as Level I cardiac resuscitation centers
at can offer a wide range of services, including timely PCI
hen indicated, a goal-directed care bundle (202,203), ther-
eutic hypothermia (157,158), frequent or continuous elec-
oencephalographic monitoring, a multidisciplinary team
proach, and neuropsychiatric evaluation for survivors. All
her participating hospitals should be trained and equipped
Level II cardiac resuscitation centers, which are capable of
itiating therapeutic hypothermia and transferring patients
r primary postresuscitation care. Ideally, out-of-hospital
rdiac arrest outcomes should be measured and compared
ithin a dedicated registry. Lastly, it is important for orga-
zations that collect and publicly report STEMI and PCI data
consider resuscitated out-of-hospital cardiac arrest patients
parately from their hospital and individual operator quality
corecards” because such patients, even with optimal care,
ve a much higher mortality rate than that of patients with
TEMI who have not had a cardiac arrest (204–206). Public
porting in this instance might have the unintended conse-
ence of reducing appropriate care (207).
. Reperfusion at a PCI-Capable Hospital
.1. Primary PCI
.1.1. Primary PCI in STEMI: Recommendations
ee Table 2 for a summary of recommendations from this
ction.
ASS I
Primary PCI should be performed in patients with STEMI and
ischemic symptoms of less than 12 hours’ duration
(82,208,209). (Level of Evidence: A)
Primary PCI should be performed in patients with STEMI and
ischemic symptoms of less than 12 hours’ duration who have
contraindications to fibrinolytic therapy, irrespective of the
time delay from FMC (210,211). (Level of Evidence: B)
Primary PCI should be performed in patients with STEMI and
cardiogenic shock or acute severe HF, irrespective of time andelay from MI onset (Section 9.1.1) (212–215). (Level of
Evidence: B)
ASS IIa
Primary PCI is reasonable in patients with STEMI if there is
clinical and/or ECG evidence of ongoing ischemia between
12 and 24 hours after symptom onset (94,95). (Level of
Evidence: B)
ASS III: HARM
PCI should not be performed in a noninfarct artery at the time
of primary PCI in patients with STEMI who are hemodynami-
cally stable (216–218). (Level of Evidence: B)
rimary PCI of the infarct artery is preferred to fibrinolytic
erapy when time-to-treatment delays are short and the patient
esents to a high-volume, well-equipped center with experi-
ced interventional cardiologists and skilled support staff.
ompared with fibrinolytic therapy, primary PCI produces
gher rates of infarct artery patency, TIMI 3 flow, and access
te bleeding and lower rates of recurrent ischemia, reinfarction,
ergency repeat revascularization procedures, intracranial
morrhage (ICH), and death (82). Early, successful PCI also
eatly decreases the complications of STEMI that result from
nger ischemic times or unsuccessful fibrinolytic therapy, al-
wing earlier hospital discharge and resumption of daily activ-
es. Primary PCI has its greatest survival benefit in high-risk
tients. PCI outcomes have been shown to be worse with
lays to treatment and with low-volume hospitals and opera-
rs. Quality metrics for both laboratory and operator perfor-
ance and considerations with regard to primary PCI at hospi-
ls without on-site cardiac surgery are reviewed in the 2011
CCF/AHA/SCAI Guideline for Percutaneous Coronary Inter-
ntion, Section 7 (219).
Potential complications of primary PCI include problems
ith the arterial access site; adverse reactions to volume
ading, contrast medium, and antithrombotic medications;
chnical complications; and reperfusion events. The “no-
flow” phenomenon refers to suboptimal myocardial perfu-
on despite restoration of epicardial flow in the infarct artery
ble 2. Primary PCI in STEMI
COR LOE References
hemic symptoms 12 h I A (82,208,209)
hemic symptoms 12 h and
ntraindications to fibrinolytic
erapy irrespective of time delay
m FMC
I B (210,211)
rdiogenic shock or acute severe HF
espective of time delay from MI
set
I B (212–215)
idence of ongoing ischemia 12 to
h after symptom onset
IIa B (94,95)
I of a noninfarct artery at the time
primary PCI in patients without
modynamic compromise
III: Harm B (216–218)
COR indicates Class of Recommendation; FMC, first medical contact; HF,
art failure; LOE, Level of Evidence; MI, myocardial infarction; PCI, percuta-
ous coronary intervention; and STEMI, ST-elevation myocardial infarction.d has been attributed to the combined effects of inflamma-
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asm, and myocyte reperfusion injury (220). No-reflow is
sociated with a reduced survival rate. Treatment and pre-
ntion strategies have included use of the GP IIb/IIIa
tagonist abciximab, vasodilators (nitroprusside, verapamil,
enosine), and inhibitors of various metabolic pathways
icorandil, pexelizumab), albeit without consistent effect.
anual thrombus aspiration at the time of primary PCI
sults in improved tissue perfusion and more complete ST
solution (221,222) (Section 4.2), though not all studies have
own positive results (223).
PCI of a noninfarct artery with TIMI 3 flow at the time of
imary PCI in hemodynamically stable patients has been
sociated with worse clinical outcomes in several studies,
16–218,224) though others have suggested that it may be
rformed safely (225–229). Noninfarct artery PCI is not
commended in this context unless multiple complex lesions
e seen on angiography and ECG localization of the infarct
ambiguous (230,231). Clinical stability may be defined
oadly as the absence of low output, hypotension, persistent
chycardia, apparent shock, high-grade ventricular or symp-
matic supraventricular tachyarrhythmias, and spontaneous
current ischemia. In patients with cardiogenic shock due to
mp failure, PCI of a severe stenosis in a large noninfarct
tery might improve hemodynamic stability and should be
nsidered during the primary procedure (Section 9.1.1). In
e majority of patients, delayed PCI can be performed in a
ninfarct artery at a later time if indicated by clinical events
the results of noninvasive testing (218,232,233).
.2. Aspiration Thrombectomy:
ecommendation
ASS IIa
Manual aspiration thrombectomy is reasonable for patients
undergoing primary PCI (221,223,234,235). (Level of Evi-
dence: B)
wo RCTs (221,235) and a meta-analysis (234) support the
e of manual aspiration thrombectomy during primary PCI to
prove microvascular reperfusion and to decrease deaths and
verse cardiac events. However, infarct size was not reduced by
anual aspiration thrombectomy in the INFUSE-AMI (Intra-
ronary Abciximab Infusion and Aspiration Thrombectomy in
atients Undergoing Percutaneous Coronary Intervention for
nterior ST-Segment Elevation Myocardial Infarction) trial of
tients with large anterior STEMI (223). The trial was under-
wered to detect differences in clinical outcomes. No clinical
nefit for routine rheolytic thrombectomy has been demon-
rated in primary PCI (234,236,237).
.3. Use of Stents in Primary PCI
.3.1. Use of Stents in Patients With STEMI:
ecommendations
ASS I
Placement of a stent (bare-metal stent [BMS] or drug-eluting
stent [DES]) is useful in primary PCI for patients with STEMI
(238,239). (Level of Evidence: A) †BBMS† should be used in patients with high bleeding risk,
inability to comply with 1 year of dual antiplatelet therapy
(DAPT), or anticipated invasive or surgical procedures in the
next year. (Level of Evidence: C)
ASS III: HARM
DES should not be used in primary PCI for patients with STEMI
who are unable to tolerate or comply with a prolonged course
of DAPT because of the increased risk of stent thrombosis with
premature discontinuation of one or both agents (240–246).
(Level of Evidence: B)
oronary stents are used routinely at the time of primary PCI.
ompared with balloon angioplasty, BMS implantation dur-
g primary PCI decreases the risk for subsequent target-
sion and target-vessel revascularization and possibly the
sk for reinfarction, but is not associated with a reduction in
e mortality rate (238). Compared with BMS, DES implan-
tion decreases restenosis rates and the need for reinterven-
on but does not definitively reduce rates of death or
infarction. Notably, DES in this setting does not increase
e risk of early or late stent thrombosis (242–245,247,248).
ontroversy remains as to whether the risk of very late stent
rombosis is higher with first-generation DES than with
MS (249). The lowest rates of stent thrombosis have been
ported with cobalt-chromium everolimus-eluting stents
50). The greatest challenge in deciding the approach at
e time of primary PCI, however, is determining emer-
ntly whether the patient is a candidate for a prolonged
.e., 1-year) course of DAPT. DES should be avoided in
e presence of financial or social barriers that may limit
tient compliance, elevated bleeding risk, the anticipated
ed for invasive or surgical procedures in the subsequent
ar, or an independent indication for long-term anticoag-
ant therapy.
.4. Adjunctive Antithrombotic Therapy for
rimary PCI
ee Table 3 for a summary of recommendations from this
ction and Online Data Supplement 3 for additional infor-
ation on antithrombotic therapy.
.4.1. Antiplatelet Therapy to Support Primary PCI
r STEMI: Recommendations
ASS I
Aspirin 162 to 325 mg should be given before primary PCI
(251–253). (Level of Evidence: B)
After PCI, aspirin should be continued indefinitely (254,255,257).
(Level of Evidence: A)
A loading dose of a P2Y12 receptor inhibitor should be given as
early as possible or at time of primary PCI to patients with
STEMI. Options include
a. Clopidogrel 600 mg (253,258,259) (Level of Evidence: B); or
b. Prasugrel 60 mg (260) (Level of Evidence: B); or
c. Ticagrelor 180 mg (261). (Level of Evidence: B)
P2Y12 inhibitor therapy should be given for 1 year to patients
with STEMI who receive a stent (BMS or DES) during primary
PCI using the following maintenance doses:alloon angioplasty without stent placement may be used in selected patients.
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COR LOE References
tiplatelet therapy
pirin
162- to 325-mg load before procedure I B (251–253)
81- to 325-mg daily maintenance dose (indefinite)* I A (254,255,257)
81 mg daily is the preferred maintenance dose* IIa B (253,254,263,264)
Y12 inhibitors
Loading doses
Clopidogrel: 600 mg as early as possible or at time of PCI I B (253,258,259)
Prasugrel: 60 mg as early as possible or at time of PCI I B (260)
Ticagrelor: 180 mg as early as possible or at time of PCI I B (261)
Maintenance doses and duration of therapy
S placed: Continue therapy for 1 y with:
Clopidogrel: 75 mg daily I B (260,262)
Prasugrel: 10 mg daily I B (262)
Ticagrelor: 90 mg twice a day* I B (261)
S† placed: Continue therapy for 1 y with:
Clopidogrel: 75 mg daily I B (260,262)
Prasugrel: 10 mg daily I B (262)
Ticagrelor: 90 mg twice a day* I B (261)
S placed:
Clopidogrel, prasugrel, or ticagrelor* continued beyond 1 y IIb C N/A
Patients with STEMI with prior stroke or TIA: prasugrel III: Harm B (260)
GP IIb/IIIa receptor antagonists in conjunction with UFH or bivalirudin in selected patients
Abciximab: 0.25-mg/kg IV bolus, then 0.125 mcg/kg/min (maximum 10 mcg/min) IIa A (265–267)
Tirofiban: (high-bolus dose): 25-mcg/kg IV bolus, then 0.15 mcg/kg/min IIa B (268,269)
● In patients with CrCl 30 mL/min, reduce infusion by 50%
Eptifibatide: (double bolus): 180-mcg/kg IV bolus, then 2 mcg/kg/min; a second 180-mcg/kg bolus is
administered 10 min after the first bolus
IIa B (270)
● In patients with CrCl 50 mL/min, reduce infusion by 50%
● Avoid in patients on hemodialysis
Pre–catheterization laboratory administration of IV GP IIb/IIIa receptor antagonist IIb B (103,268,271–277)
Intracoronary abciximab 0.25-mg/kg bolus IIb B (223,278–284)
ticoagulant therapy
UFH: I C N/A
● With GP IIb/IIIa receptor antagonist planned: 50- to 70-U/kg IV bolus to achieve therapeutic ACT‡
● With no GP IIb/IIIa receptor antagonist planned: 70- to 100-U/kg bolus to achieve therapeutic ACT§ I C N/A
Bivalirudin: 0.75-mg/kg IV bolus, then 1.75–mg/kg/h infusion with or without prior treatment with UFH. An
additional bolus of 0.3 mg/kg may be given if needed.
● Reduce infusion to 1 mg/kg/h with estimated CrCl 30 mL/min
I B (248)
● Preferred over UFH with GP IIb/IIIa receptor antagonist in patients at high risk of bleeding IIa B (248)
Fondaparinux: not recommended as sole anticoagulant for primary PCI III: Harm B (304)
*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily.
†Balloon angioplasty without stent placement may be used in selected patients. It might be reasonable to provide P2Y12 inhibitor therapy to patients with STEMI
dergoing balloon angioplasty alone according to the recommendations listed for BMS. (LOE: C).
‡The recommended ACT with planned GP IIb/IIIa receptor antagonist treatment is 200 to 250 s.
§The recommended ACT with no planned GP IIb/IIIa receptor antagonist treatment is 250 to 300 s (HemoTec device) or 300 to 350 s (Hemochron device).
ACT indicates activated clotting time; BMS, bare-metal stent; CrCl, creatinine clearance; COR, Class of Recommendation; DES, drug-eluting stent; GP, glycoprotein;
, intravenous; LOE, Level of Evidence; N/A, not available; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic
tack; and UFH, unfractionated heparin.
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b. Prasugrel 10 mg daily (262) (Level of Evidence: B); or
c. Ticagrelor 90 mg twice a day (261).‡ (Level of Evidence: B)
ASS IIa
It is reasonable to use 81 mg of aspirin per day in preference to
higher maintenance doses after primary PCI (253,254,263,264).
(Level of Evidence: B)
It is reasonable to begin treatment with an intravenous GP
IIb/IIIa receptor antagonist such as abciximab (265–267)
(Level of Evidence: A), high-bolus-dose tirofiban (268,269)
(Level of Evidence: B), or double-bolus eptifibatide (270) (Level
of Evidence: B) at the time of primary PCI (with or without
stenting or clopidogrel pretreatment) in selected patients with
STEMI who are receiving unfractionated heparin (UFH).
ASS IIb
It may be reasonable to administer intravenous GP IIb/IIIa
receptor antagonist in the precatheterization laboratory set-
ting (e.g., ambulance, ED) to patients with STEMI for whom
primary PCI is intended (103,268,271–277). (Level of Evi-
dence: B)
It may be reasonable to administer intracoronary abciximab to
patients with STEMI undergoing primary PCI (223,278–284).
(Level of Evidence: B)
Continuation of a P2Y12 inhibitor beyond 1 year may be
considered in patients undergoing DES placement. (Level of
Evidence: C)
ASS III: HARM
Prasugrel should not be administered to patients with a history
of prior stroke or transient ischemic attack (260). (Level of
Evidence: B)
lthough the minimum effective aspirin dose in the setting of
CI for STEMI has not been established prospectively, the
riting committee recommends that an empiric dose of 325 mg
given as early as possible before PCI and a maintenance dose
ntinued indefinitely thereafter. It is the consensus of the
riting committee that the 81-mg maintenance dose is preferred
en among patients who receive a stent during primary PCI.
his recommendation is based on evidence of an increased risk
bleeding in most studies comparing higher- with lower-dose
pirin (253,254,263,264), as well as the absence of data from
CTs demonstrating superior efficacy of higher aspirin doses in
is setting. However, because the CURRENT-OASIS 7 (Clopi-
grel Optimal Loading Dose Usage to Reduce Recurrent
vents–Organization to Assess Strategies in Ischemic Syn-
omes) trial did not report differences in either efficacy or safety
patients with STEMI randomized to 81 mg versus 325 mg of
pirin, the committee did not think that the evidence favoring
mg over higher dosages was sufficiently conclusive to merit
Class I recommendation (253).
Loading doses of P2Y12 inhibitors are provided before or
the time of primary PCI. These agents are continued in a
aintenance dose for 1 year after PCI with a stent (BMS or
ES) in the absence of bleeding. A 600-mg loading dose of
opidogrel is preferred to a 300-mg loading dose, given thearhe recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily.ore extensive and rapid platelet inhibition achieved with the
gher dose, as well as the beneficial effects reported in a
URRENT-OASIS 7 subgroup analysis (259). The under-
wered ARMYDA-6 MI (Antiplatelet Therapy for Reduc-
on of Myocardial Damage During Angioplasty–Myocardial
farction) study also reported beneficial surrogate outcomes
ith the higher clopidogrel loading dose (258).
The antiplatelet response to clopidogrel may vary as a
nction of patient phenotype (obesity, diabetes mellitus),
teric ABCB 1 polymorphisms, hepatic CYP450 enzyme
stem polymorphisms (predominantly CYP 2C19*2), and
edications that interfere with clopidogrel biotransformation.
pproximately 25% to 30% of patients may harbor a
duced-function CYP2C19 allele. In TRITON-TIMI 38
rial to Assess Improvement in Therapeutic Outcomes by
ptimizing Platelet Inhibition with Prasugrel—Thrombolysis In
yocardial Infarction) (285) and 3 cohort studies (286–288),
tients who were carriers of the reduced-function CYP2C19*2
lele had significantly lower levels of the active metabolite of
opidogrel, diminished platelet inhibition, and increased rates of
ajor adverse cardiovascular events and stent thrombosis (285).
he U.S. Food and Drug Administration has changed clopi-
grel’s prescribing information to highlight the potential impact
CYP2C19 genotype on clopidogrel pharmacokinetics and
inical response (289). Nevertheless, other studies have not
nfirmed associations between CYP2C19 polymorphisms and
verse outcomes in clopidogrel-treated patients (290). Future
udies are needed to further clarify the risk associated with these
netic polymorphisms and to develop effective therapeutic
rategies for carriers of allelic variants of responsible enzyme
stems. Proton-pump inhibitors, most prominently omeprazole,
n interfere with clopidogrel metabolism and result in dimin-
hed in vitro antiplatelet effect (291), but it does not appear that
is pharmacokinetic effect translates into worse clinical out-
mes (291,292).
Prasugrel, an alternative thienopyridine, achieves greater
hibition of platelet aggregation than clopidogrel. In the
RITON-TIMI 38 trial(260) of prasugrel versus clopidogrel
patients with ACS for whom an invasive strategy was
anned, patients with STEMI who were assigned to prasug-
l had a lower 30-day rate of the composite primary
tcome. This difference persisted to 15 months. In addition,
e rate of stent thrombosis reported at 30 days was signifi-
ntly lower with prasugrel (260,262). The loading dose of
opidogrel in TRITON-TIMI 38, which rarely was adminis-
red before coronary angiography and was limited to 300
g, may have contributed to differences in efficacy and safety
tween treatment groups (262).
The benefits of prasugrel relative to clopidogrel in STEMI
ust be weighed against the increase in the risk of bleeding
sociated with its use. Prasugrel should not be administered
patients with a history of stroke or transient ischemic attack
d was not shown to be beneficial in patients 75 years of
e or patients who weigh 60 kg (260). In TRITON-TIMI
, interaction testing for efficacy and safety showed no
gnificant difference in bleeding risk across the spectrum of
CS. Prasugrel may be best suited for younger patients with
abetes mellitus or large areas of myocardium at risk, who
e also at low bleeding risk, have the ability to continue a
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e subsequent year. The package insert for prasugrel sug-
sts that a lower maintenance dose of 5 mg daily might be
nsidered for patients at high risk of bleeding, though this
se has not been prospectively studied (293).
Ticagrelor is a reversible, nonthienopyridine P2Y12 recep-
r antagonist that does not require metabolic conversion to
tive drug. The PLATO (Platelet Inhibition and Patient
utcomes) study compared ticagrelor (180-mg loading dose,
mg twice daily thereafter) with clopidogrel (300- or
0-mg loading dose, 75 mg daily thereafter) for the preven-
on of cardiovascular events in 18,624 patients with ACS, of
hom 35% had STEMI (294). Among the 7544 patients
rolled with ST elevation or LBBB who underwent primary
CI, findings were consistent with the overall trial results.
ignificant reductions favoring ticagrelor were seen in the
imary PCI subgroup for stent thrombosis and total deaths,
ough there were more strokes and episodes of ICH with
cagrelor (261). A prespecified subgroup analysis in the
LATO trial showed a significant interaction between treat-
ent effect and geographic region, with an apparently smaller
cagrelor effect in North America than in other areas.
lthough this interaction could have been due to chance
one (295), a contribution from higher aspirin doses, as more
mmonly used in the United States, cannot be excluded.
hen provided long term with ticagrelor as a component of
APT, the dose of aspirin should not exceed 100 mg (293).
Although 1 year of DAPT is recommended after stent
plantation during primary PCI for STEMI, earlier discon-
nuation of a P2Y12 inhibitor may be necessary if the risk of
orbidity from bleeding outweighs the anticipated benefit of
APT. Clinical judgment is required, and discussion with the
terventional cardiologist is recommended.
DAPT with aspirin and either clopidogrel or prasugrel has
creased the risk of ICH in several clinical trials and patient
pulations (especially in those with prior stroke) (260,296–
8). In PLATO, the number of patients with prior stroke was
all, limiting the power to detect treatment differences in
tracranial bleeding in this subgroup (299). Until further data
come available, it would seem prudent to weigh the
ssible increased risk of intracranial bleeding when the
dition of ticagrelor to aspirin is considered in patients with
ior stroke or transient ischemic attack (300).
Evidence to support the use of intravenous GP IIb/IIIa
ceptor antagonists in patients with STEMI was established
rgely before the use of oral DAPT. Although several studies
ve failed to show benefit with the administration of “up-
ream” GP IIb/IIIa receptor antagonists before primary PCI in
e setting of DAPT with either UFH or bivalirudin anticoagu-
tion, (103,268,271–276) a meta-analysis restricted to the use of
ciximab has suggested it may be useful in this setting (277).
he adjunctive use of GP IIb/IIIa agents at the time of PCI can
considered on an individual basis for large thrombus burden
inadequate P2Y12 receptor antagonist loading (265–270,301).
or patients receiving bivalirudin as the primary anticoagulant,
utine adjunctive use of GP IIb/IIIa inhibitors is not recom-
ended (248) but may be considered as adjunctive or “bail-out”
erapy in selected cases (223,301–303). Studies of intracoro-
ry GP IIb/IIIa administration during primary PCI have shownixed results for a variety of surrogate and combined clinical
dpoints. Use of intracoronary abciximab may be reasonable in
lect cases (223,278–284).
.4.2. Anticoagulant Therapy to Support Primary PCI:
ecommendations
ASS I
For patients with STEMI undergoing primary PCI, the following
supportive anticoagulant regimens are recommended:
a. UFH, with additional boluses administered as needed to
maintain therapeutic activated clotting time levels, taking
into account whether a GP IIb/IIIa receptor antagonist has
been administered (Level of Evidence: C); or
b. Bivalirudin with or without prior treatment with UFH (248).
(Level of Evidence: B)
ASS IIa
In patients with STEMI undergoing PCI who are at high risk of
bleeding, it is reasonable to use bivalirudin monotherapy in
preference to the combination of UFH and a GP IIb/IIIa
receptor antagonist (248). (Level of Evidence: B)
ASS III: HARM
Fondaparinux should not be used as the sole anticoagulant to
support primary PCI because of the risk of catheter thrombosis
(304). (Level of Evidence: B)
travenous UFH titrated to an appropriate activated clotting
e is a familiar and well-tested strategy for anticoagulant
erapy at the time of PCI for STEMI. Enoxaparin and fonda-
rinux have been studied less extensively in this setting. The
TOLL (Acute STEMI Treated with Primary PCI and IV
noxaparin or UFH to Lower Ischemic and Bleeding Events at
hort- and Long-term Follow-up) trial comparing intravenous
oxaparin with UFH for primary PCI failed to meet its primary,
mposite endpoint (305). Fondaparinux has been associated with
theter thrombosis in this setting (304). On the basis of the findings
the HORIZONS-AMI (Harmonizing Outcomes with Revascu-
rization and Stents in Acute Myocardial Infarction) trial (248), the
riting committee considers bivalirudin, in combination with oral
APT, a reasonable anticoagulant alternative for primary PCI in
EMI, regardless of whether pretreatment was given with UFH,
pecially for patients at higher risk of bleeding and when avoidance
GP IIb/IIIa antagonists is desired. Bivalirudin in this setting may
ovide a long-term survival benefit related to decreased bleeding
t with a higher risk of early stent thrombosis (248).
. Reperfusion at a Non–PCI-Capable
ospital
.1. Fibrinolytic Therapy When There Is an
nticipated Delay to Performing Primary PCI
ithin 120 Minutes of FMC: Recommendations
ee Table 4 for a summary of recommendations from this
ction.
ASS I
In the absence of contraindications, fibrinolytic therapy should
be given to patients with STEMI and onset of ischemic symp-
toms within the previous 12 hours when it is anticipated that
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(81,306–311). (Level of Evidence: A)
ASS IIa
In the absence of contraindications and when PCI is not
available, fibrinolytic therapy is reasonable for patients with
STEMI if there is clinical and/or ECG evidence of ongoing
ischemia within 12 to 24 hours of symptom onset and a large
area of myocardium at risk or hemodynamic instability. (Level
of Evidence: C)
ASS III: HARM
Fibrinolytic therapy should not be administered to patients with
ST depression except when a true posterior (inferobasal) MI is
suspected or when associated with ST elevation in lead aVR
(10,11,81,312,313). (Level of Evidence: B)
.1.1. Timing of Fibrinolytic Therapy
he benefits of fibrinolytic therapy in patients with ST
evation or bundle-branch block MI are well established,
ith a time-dependent reduction in both mortality and mor-
dity rates during the initial 12 hours after symptom onset
1,306–311,314–320). As noted in Section 3.2, even when
terhospital transport times are short, there may be advan-
ges to the immediate delivery of fibrinolytic therapy versus
y delay to primary PCI for patients with STEMI and low
eeding risk who present within the first 1 to 2 hours of
ble 4. Indications for Fibrinolytic Therapy When There Is a
120-Minute Delay From FMC to Primary PCI (Figure 2)
COR LOE References
hemic symptoms 12 h I A (81,306–311)
idence of ongoing ischemia 12 to 24 h
ter symptom onset and a large area of
yocardium at risk or hemodynamic
stability
IIa C N/A
depression, except if true posterior
ferobasal) MI is suspected or when
sociated with ST elevation in lead aVR
III: Harm B (10,11,81,
312,313)
COR indicates Class of Recommendation; FMC, first medical contact; LOE,
vel of Evidence; MI, myocardial infarction; N/A, not available; and PCI,
rcutaneous coronary intervention.
ble 5. Fibrinolytic Agents
Fibrinolytic Agent Dose
brin-specific:
Tenecteplase (TNK-tPA) Single IV weight-based bolus†
Reteplase (rPA) 10 U10-U IV boluses given 30 min apar
Alteplase (tPA) 90-min weight-based infusion‡
n–fibrin-specific:
Streptokinase§ 1.5 million units IV given over 30–60 min
*Strength of fibrin specificity; “” is more strong, “” is less stro
†30 mg for weight 60 kg; 35 mg for 60–69 kg; 40 mg for 70–79 kg; 45
‡Bolus 15 mg, infusion 0.75 mg/kg for 30 min (maximum 50 mg), then 0.5
§Streptokinase is no longer marketed in the United States but is available in
Streptokinase is highly antigenic and absolutely contraindicated within 6 mo
IV indicates intravenous; rPA, reteplase plasminogen activator; TIMI, Throm
tivator; and tPA, tissue-type plasminogen activator.mptom onset (123,321). Benefit from fibrinolytic therapy in
tients who present 12 hours after symptom onset has not
en established (81,307,309,322,323), although there re-
ains consensus that consideration should be given to ad-
inistering a fibrinolytic agent in symptomatic patients pre-
nting 12 hours after symptom onset with STEMI and a
rge area of myocardium at risk or hemodynamic instability
PCI is unavailable (4,48).
.1.2. Choice of Fibrinolytic Agent
able 5 lists currently available fibrinolytic agents (314,324–
6,328,329). Fibrin-specific agents are preferred when avail-
le. Adjunctive antiplatelet and/or anticoagulant therapies
e indicated, regardless of the choice of fibrinolytic agent.
.1.3. Contraindications and Complications With
ibrinolytic Therapy
bsolute and relative contraindications to fibrinolytic therapy
e listed in Table 6. The decision to use fibrinolytic therapy
r patients with STEMI is predicated on a risk–benefit
alysis that integrates time from onset of symptoms, the
inical and hemodynamic features at presentation, patient
morbidities, risk of bleeding, presence of contraindications,
d time delay to PCI (Section 3.2).
.1.4. Adjunctive Antithrombotic Therapy With
ibrinolysis
ee Table 7 for a summary of recommendations from this
ction.
.1.4.1. ADJUNCTIVE ANTIPLATELET THERAPY WITH
BRINOLYSIS: RECOMMENDATIONS
ASS I
Aspirin (162- to 325-mg loading dose) and clopidogrel (300-mg
loading dose for patients <75 years of age, 75-mg dose for
patients >75 years of age) should be administered to patients
with STEMI who receive fibrinolytic therapy (308,330,331).
(Level of Evidence: A)
Aspirin should be continued indefinitely (308,330,331) (Level
of Evidence: A) and clopidogrel (75 mg daily) should be
continued for at least 14 days (330,331) (Level of Evidence: A)
Fibrin
Specificity* Antigenic
Patency Rate
(90-min TIMI 2 or 3 flow)
 No 85% (328)
 No 84% (314)
 No 73% to 84% (314,324,326)
No Yes 60% to 68% (324,329)
80–89 kg; and 50 mg for 90 kg.
(maximum 35 mg) over the next 60 min; total dose not to exceed 100 mg.
ountries.
ious exposure because of the potential for serious allergic reaction.
In Myocardial Infarction; TNK-tPA, tenecteplase tissue-type plasminogent
ng.
mg for
mg/kg
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2013 ACCF/AHA STEMI Guideline: Full Text January 29, 2013:e78–140and up to 1 year (Level of Evidence: C) in patients with STEMI
who receive fibrinolytic therapy.
ASS IIa
It is reasonable to use aspirin 81 mg per day in preference to higher
maintenance doses after fibrinolytic therapy (254,257,263,264).
(Level of Evidence: B)
he beneficial effects of aspirin and clopidogrel with fibrino-
tic therapy are well established (254,257,263,264). These
ents should be given before or with the fibrinolytic (330).
he recommendation that clopidogrel be continued for up to
year is extrapolated from the experience with DAPT in
tients with non–ST-elevation ACS (330). The coadminis-
ation of other P2Y12 antagonists with fibrinolytic therapy
s not been prospectively studied.
.1.4.2. ADJUNCTIVE ANTICOAGULANT THERAPY WITH
BRINOLYSIS: RECOMMENDATIONS
ASS I
Patients with STEMI undergoing reperfusion with fibrinolytic
therapy should receive anticoagulant therapy for a minimum of
ble 6. Contraindications and Cautions for Fibrinolytic
erapy in STEMI*
solute contraindications
● Any prior ICH
● Known structural cerebral vascular lesion (e.g., arteriovenous
malformation)
● Known malignant intracranial neoplasm (primary or metastatic)
● Ischemic stroke within 3 mo
● EXCEPT acute ischemic stroke within 4.5 h
● Suspected aortic dissection
● Active bleeding or bleeding diathesis (excluding menses)
● Significant closed-head or facial trauma within 3 mo
● Intracranial or intraspinal surgery within 2 mo
● Severe uncontrolled hypertension (unresponsive to emergency
therapy)
● For streptokinase, prior treatment within the previous 6 mo
lative contraindications
● History of chronic, severe, poorly controlled hypertension
● Significant hypertension on presentation (SBP 180 mm Hg or DBP
110 mm Hg)
● History of prior ischemic stroke 3 mo
● Dementia
● Known intracranial pathology not covered in absolute contraindications
● Traumatic or prolonged (10 min) CPR
● Major surgery (3 wk)
● Recent (within 2 to 4 wk) internal bleeding
● Noncompressible vascular punctures
● Pregnancy
● Active peptic ulcer
● Oral anticoagulant therapy
*Viewed as advisory for clinical decision making and may not be all-inclusive
definitive.
CPR indicates cardiopulmonary resuscitation; DBP; diastolic blood pressure;
H, intracranial hemorrhage; SBP, systolic blood pressure; and STEMI,
-elevation myocardial infarction.48 hours, and preferably for the duration of the index hospital- prization, up to 8 days or until revascularization if performed
(318,332). (Level of Evidence: A) Recommended regimens
include
a. UFH administered as a weight-adjusted intravenous bolus
and infusion to obtain an activated partial thromboplastin
time of 1.5 to 2.0 times control, for 48 hours or until
revascularization (Level of Evidence: C);
b. Enoxaparin administered according to age, weight, and
creatinine clearance, given as an intravenous bolus, fol-
lowed in 15 minutes by subcutaneous injection for the
duration of the index hospitalization, up to 8 days or until
revascularization (332–335) (Level of Evidence: A); or
c. Fondaparinux administered with initial intravenous dose,
followed in 24 hours by daily subcutaneous injections if the
estimated creatinine clearance is greater than 30 mL/min,
for the duration of the index hospitalization, up to 8 days or
until revascularization (304). (Level of Evidence: B)
nticoagulation is recommended in support of fibrin-specific
erapy to improve vessel patency and prevent reocclusion
36). Dosing of UFH is predicated on the activated partial
romboplastin time, and monitoring of platelet counts to
oid the risks of excess bleeding and heparin-induced
rombocytopenia (HIT) is advised (318,337–339). UFH may
given as an intravenous bolus and infusion for patients
ceiving streptokinase if they are at high risk for systemic
bolization. Enoxaparin is preferred over UFH for antico-
ulation extending beyond 48 hours. Caution is advised
hen enoxaparin is administered to patients with impaired
nal function (340). Fondaparinux should not be given as the
le anticoagulant to patients referred for PCI and is contra-
dicated for patients with a creatinine clearance 30 mL/
in (304,341). Bivalirudin may be used for patients treated
ith a fibrinolytic agent who develop HIT and require
ntinued anticoagulation (342).
.2. Assessment of Reperfusion After
ibrinolysis
IMI 3 flow after fibrinolytic therapy predicts subsequent
ort- and long-term survival (343–345). Traditional vari-
les that have been used to assess the angiographic response
fibrinolytic therapy are imprecise (346) and have included
improvement in or relief of chest pain, resolution of ST
evation, and the presence of reperfusion arrhythmias (e.g.,
celerated idioventricular rhythm). The relatively sudden
d complete relief of chest pain coupled with 70% ST
solution (in the index lead showing the greatest degree of
evation on presentation) is highly suggestive of restoration
normal myocardial blood flow. Complete (or near com-
ete) ST-segment resolution at 60 or 90 minutes after
brinolytic therapy is a useful marker of a patent infarct
tery (347–351). Conversely, partial or absent improvement
the extent of ST elevation is not as accurate in predicting
“closed artery” (349–351). Lack of improvement in ST
solution is associated with worse prognosis (349,352,353).
he combination of 50% ST resolution and the absence of
perfusion arrhythmias at 2 hours after treatment predicts
IMI flow 3 in the infarct artery with a sensitivity of 81%,
ecificity 88%, positive predictive value 87%, and negative
edictive value 83% (347). Lack of resolution of ST eleva-
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ould prompt strong consideration of a decision to proceed
ith immediate coronary angiography and “rescue” PCI.
.3. Transfer to a PCI-Capable Hospital After
ibrinolytic Therapy
ee Figure 2.
.3.1. Transfer of Patients With STEMI to a
CI-Capable Hospital for Coronary Angiography
fter Fibrinolytic Therapy: Recommendations
ee Table 8 for a summary of recommendations from this
ction; Online Data Supplement 4 for additional data on
rly catheterization and rescue PCI for fibrinolytic failure in
e stent era; and Online Data Supplement 5 for additional
ta on early catheterization and PCI after fibrinolysis in the
ent era.
ASS I
Immediate transfer to a PCI-capable hospital for coronary
angiography is recommended for suitable patients with
STEMI who develop cardiogenic shock or acute severe HF,
irrespective of the time delay from MI onset (354). (Level of
ble 7. Adjunctive Antithrombotic Therapy to Support Reperfus
tiplatelet therapy
pirin
162- to 325-mg loading dose
81- to 325-mg daily maintenance dose (indefinite)
81 mg daily is the preferred maintenance dose
Y12 receptor inhibitors
Clopidogrel:
● Age 75 y: 300-mg loading dose
● Followed by 75 mg daily for at least 14 d and up to 1 y in absence of
● Age 75 y: no loading dose, give 75 mg
● Followed by 75 mg daily for at least 14 d and up to 1 y in absence of
ticoagulant therapy
UFH:
● Weight-based IV bolus and infusion adjusted to obtain aPTT of 1.5 to 2.0 t
48 h or until revascularization. IV bolus of 60 U/kg (maximum 4000 U) foll
infusion of 12 U/kg/h (maximum 1000 U) initially, adjusted to maintain aPT
times control (approximately 50 to 70 s) for 48 h or until revascularization
Enoxaparin:
● If age 75 y: 30-mg IV bolus, followed in 15 min by 1 mg/kg subcutaneo
(maximum 100 mg for the first 2 doses)
● If age 75 y: no bolus, 0.75 mg/kg subcutaneously every 12 h (maximum
first 2 doses)
● Regardless of age, if CrCl 30 mL/min: 1 mg/kg subcutaneously every 24
● Duration: For the index hospitalization, up to 8 d or until revascularization
Fondaparinux:
● Initial dose 2.5 mg IV, then 2.5 mg subcutaneously daily starting the follow
the index hospitalization up to 8 d or until revascularization
● Contraindicated if CrCl 30 mL/min
aPTT indicates activated partial thromboplastin time; COR, Class of Recomme
ailable; and UFH, unfractionated heparin.Evidence: B) inASS IIa
Urgent transfer to a PCI-capable hospital for coronary angiog-
raphy is reasonable for patients with STEMI who demonstrate
th Fibrinolytic Therapy
COR LOE References
I A (308,330,331)
I A (308,330,331)
IIa B (254,257,263,264)
I A (330,331)
I A (14 d) (330,331)
C (up to 1 y) N/A
I A (330,331)
I A (14 d) (330,331)
C (up to 1 y) N/A
I C N/A
ntrol for
an
to 2.0
I A (332–335)
ry 12 h
for the
I B (304)
, for
CrCl, creatinine clearance; IV, intravenous; LOE, Level of Evidence; N/A, not
ble 8. Indications for Transfer for Angiography After
brinolytic Therapy
COR LOE References
mediate transfer for cardiogenic shock or
vere acute HF irrespective of time delay
m MI onset
I B (354)
gent transfer for failed reperfusion or
occlusion
IIa B (346,355–357)
part of an invasive strategy in stable*
tients with PCI between 3 and 24 h after
ccessful fibrinolysis
IIa B (358–363)
*Although individual circumstances will vary, clinical stability is defined by
e absence of low output, hypotension, persistent tachycardia, apparent
ock, high-grade ventricular or symptomatic supraventricular tachyarrhyth-
ias, and spontaneous recurrent ischemia.
COR indicates Class of Recommendation; HF, heart failure; LOE, Level of
idence; MI, myocardial infarction; and PCI, percutaneous coronaryion Wi
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therapy (346,355–357). (Level of Evidence: B)
Transfer to a PCI-capable hospital for coronary angiography is
reasonable for patients with STEMI who have received fibrino-
lytic therapy even when hemodynamically stable§ and with
clinical evidence of successful reperfusion. Angiography can be
performed as soon as logistically feasible at the receiving
hospital, and ideally within 24 hours, but should not be
performed within the first 2 to 3 hours after administration of
fibrinolytic therapy (358–363). (Level of Evidence: B)
.3.1.1. TRANSFER FOR CARDIOGENIC SHOCK
he SHOCK (Should We Emergently Revascularize Oc-
uded Coronaries for Cardiogenic Shock) trial (354) demon-
rated benefit with coronary angiography and emergency
vascularization (with either PCI or CABG) compared with
mediate medical stabilization and delayed revasculariza-
on in patients with ST-elevation/Q-wave or new LBBB MI
d cardiogenic shock (Section 9.1.1). Of note, nearly 50% of
tients randomized to the emergency revascularization arm
ceived preprocedural fibrinolytic therapy, and the benefit of
ergency revascularization was similar for patients transferred
rsus those admitted directly to a PCI-capable hospital. For
tients with cardiogenic shock, the benefit of emergency
vascularization was apparent across a very wide time window,
tending up to 54 hours after MI and 18 hours after shock onset
54). Although PCI should be performed as soon as possible
ter MI and shock onset, the time window for benefit in this
inical context is more prolonged because of the ongoing
ownward ischemic spiral” associated with shock.
.3.1.2. TRANSFER FOR FAILURE OF FIBRINOLYTIC
HERAPY
everal trials in the stent era and several meta-analyses have
amined the role of PCI for fibrinolytic failure (346,355–
7,364) (Online Data Supplement 4). These studies report a
end toward a lower mortality rate and significantly lower
tes of recurrent MI and HF among patients treated with
scue PCI for failed fibrinolysis. For example, in the REACT
apid Early Action for Coronary Treatment) study (355),
7 patients who failed to demonstrate evidence of reperfu-
on at 90 minutes by ECG criteria were randomized to 1 of
treatment arms: rescue PCI, conservative care, or repeat
brinolytic therapy. The primary endpoint, a composite of
ath, reinfarction, stroke, or severe HF at 6 months, was
gnificantly lower among patients randomized to rescue PCI
an among those randomized to conservative care or repeat
brinolysis (event-free survival rate: 84.6% versus 70.1%
rsus 68.7%, p0.004). The benefit was driven primarily by
reduction in reinfarction; there was no significant survival
nefit. Minor bleeding was significantly higher among
tients randomized to rescue PCI; however, there were no
fferences in major bleeding among the 3 groups. Other
udies have reported higher rates of periprocedural bleeding
d stroke in patients undergoing rescue PCI than in patients
lthough individual circumstances will vary, clinical stability is defined by the
sence of low output, hypotension, persistent tachycardia, apparent shock, high-
ade ventricular or symptomatic supraventricular tachyarrhythmias, and spontane-cas recurrent ischemia.eated conservatively (346,356). The benefit of transferring a
tient for PCI of a persistently occluded infarct artery likely
ould justify these risks if cardiogenic shock, significant
potension, severe HF, or ECG evidence of an extensive
ea of myocardial jeopardy (including an anterior infarction
inferior infarction with either right ventricular [RV]
volvement or anterior precordial ST depression) is present.
these circumstances, the benefits are greatest if PCI is
itiated early after fibrinolytic failure. On the other hand,
nservative treatment might be reasonable in a patient with
proving symptoms and a limited inferior infarction despite
rsistence of ST elevation.
.3.1.3. TRANSFER FOR ROUTINE EARLY CORONARY
NGIOGRAPHY AFTER FIBRINOLYTIC THERAPY
ith the introduction of coronary stents and aggressive
tiplatelet therapies, there has been renewed interest in
mediate and early catheterization after fibrinolytic therapy.
he advantage of this approach is that it can be initiated at
n–PCI-capable hospitals and affords the healthcare system
ditional time to arrange a “nonemergency” transfer for
giography and PCI. Routine referral for angiography with
e intent to perform PCI is supported indirectly by retrospec-
ve analyses from trials of fibrinolytic therapy that suggest
at patients treated with PCI during the index hospitalization
ve a lower risk of recurrent MI and a lower 2-year mortality
te (365–367). The results of RCTs evaluating a strategy of
utine catheterization after fibrinolysis are limited by small
mple sizes or surrogate endpoints and have provided mixed
sults. Nevertheless, most trials have demonstrated improve-
ent in clinical outcomes in patients transferred for early
theterization, most notably in higher-risk patients (357–
2,368–371) (Table 8 and Figure 3). In the GRACIA (Grup
Analisis de la Cardiopatia Isquemica Aguda) study (362),
rly catheterization within 6 to 24 hours of successful
brinolysis in stable patients was compared with an ischemia-
ided approach. It resulted in improved outcomes, including
significantly lower rate of death, reinfarction, or ischemia-
iven revascularization at 1 year.
The TRANSFER-AMI (Trial of Routine Angioplasty and
tenting after Fibrinolysis to Enhance Reperfusion in Acute
yocardial Infarction) study (360) was the largest (n1059)
the RCTs evaluating transfer for coronary angiography and
vascularization among high-risk patients and showed a
gnificant reduction in the combined primary endpoint of
ath, recurrent MI, recurrent ischemia, new or worsening
F, or shock at 30 days with immediate transfer for the
giography group compared with conservative care. The
ndings from this and other studies indicate that high-risk
tients with STEMI appear to benefit from immediate
ansfer for early catheterization, compared with either an
chemia-guided approach or delayed routine catheterization
24 hours to 2 weeks (360,361). The reported benefits relate to a
duction in the incidence of recurrent infarction or ischemia, thus
voring earlier transfer and revascularization when possible.
The NORDISTEMI (Norwegian Study on District Treat-
ent of ST-Elevation Myocardial Infarction) investigators
58) examined the effect of immediate routine transfer for
theterization versus a conservative strategy with either
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transfer for rescue PCI. Although this study failed to
monstrate a significant difference between the 2 treat-
ent groups in the incidence of the primary composite
dpoint of death, recurrent MI, stroke, or new or recurrent
chemia at 12 months, the incidence of death, recurrent
I, or stroke was significantly lower in the immediate-
ansfer group. Furthermore, the magnitude of reduction in
sk was similar to that reported for high-risk patients in
e TRANSFER-AMI study (RR: 0.64; 95% CI: 0.47 to
87; p0.004) (360).
In a meta-analysis (359) that included 7 RCTs of early
ansfer for catheterization, a strategy of routine early cathe-
rization after fibrinolysis was associated with a statisti-
lly significant reduction in the incidence of death or MI
30 days and at 1 year, without an increase in the risk of
ajor bleeding. This meta-analysis was based on a mixture
trials that randomized high-risk patients (360,361,369)
d trials that did not mandate the inclusion of high-risk
bjects. A meta-regression analysis investigating the
lative benefit of an invasive strategy after fibrinolysis
cording to the baseline risk of the enrolled patients for
ch trial suggested a larger proportional benefit with early
theterization and PCI in trials enrolling higher-risk
tients (359).
It is important to recognize that the clinical trials that have
dressed routine invasive evaluation after initial pharmacolog-
al management used a time window of 0 to 24 hours for the
gure 3. Primary outcome of trials of routine versus ischemia-driven
e depicts the results of trials comparing routine early catheterization
utine delayed catheterization. The y-axis represents the percentage
e includes the average (or median) time from fibrinolytic therapy to
nts enrolled in the study (all patients or high-risk patients), the dura
dpoint for each trial. The darker bars represent patients who under
rs represent patients who underwent either an ischemia-guided or
APITAL-AMI, Combined Angioplasty and Pharmacological Intervent
-AMI, Combined Abciximab Reteplase Stent Study in Acute Myocar
Analisis de la Cardiopatia Isquemica Aguda; MI, myocardial infarction
yocardial Infarction; PCI, percutaneous coronary intervention; revasc, is
vascularization; TRANSFER-AMI, Trial of Routine Angioplasty and Sten
n; SIAM-3, Southwest German Interventional Study In Acute Myocardi
erapy (358,360–362,368–370). Reproduced with permission from Graarly invasive” strategy, thus supporting earlier transfer after seministration of fibrinolytic therapy even for patients without
gh-risk features. However, this time window likely was used in
e trial designs to create the greatest possible difference in
tcome when compared with the control group (rather
an an a priori expectation that the benefit would be
iven entirely in 24 hours). The writing committee
lieves that there likely will be continued benefit even
yond 24 hours in those patients with a patent but stenotic
farct artery. In stable patients who are not transferred
mediately, catheterization can be considered as part of a
utine pharmacoinvasive or ischemia-guided approach
24 hours after administration of fibrinolytic therapy.
ecause of the associated increased bleeding risk, very
rly (2 to 3 hours) catheterization after administration
fibrinolytic therapy with intent to perform revascular-
ation should be reserved for patients with evidence of
iled fibrinolysis and significant myocardial jeopardy for
hom rescue PCI would be appropriate.
. Delayed Invasive Management
.1. Coronary Angiography in Patients Who
itially Were Managed With Fibrinolytic
herapy or Who Did Not Receive Reperfusion:
ecommendations
ee Table 9 for a summary of recommendations from this
layed) catheterization and PCI after fibrinolytic therapy. The Fig-
brinolytic therapy with either an ischemia-driven approach or
ents who experienced 1 of the clinical trial endpoints. The Fig-
e number of patients randomized in each study, the type of pa-
follow-up for the primary endpoint, and the composite primary
utine early catheterization after fibrinolytic therapy. The lighter
delayed catheterization approach. arrhy indicates arrhythmia;
sus Thrombolysis Alone in Acute Myocardial Infarction; CARESS-
arction; CHF, congestive heart failure; D, death; GRACIA, Grup
ISTEMI, Norwegian study on District treatment of ST-Elevation
-driven revascularization; RI, recurrent ischemia; TLR, target-lesion
er Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarc-
tion; and WEST, Which Early ST-Elevated Myocardial Infarction
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Cardiac catheterization and coronary angiography with intent
to perform revascularization should be performed after STEMI
in patients with any of the following:
a. Cardiogenic shock or acute severe HF that develops after
initial presentation (215,354,372,373) (Level of Evidence: B);
b. Intermediate- or high-risk findings on predischarge noninvasive
ischemia testing (232,233) (Level of Evidence: B); or
c. Myocardial ischemia that is spontaneous or provoked by mini-
mal exertion during hospitalization. (Level of Evidence: C)
ASS IIa
Coronary angiography with intent to perform revascularization
is reasonable for patients with evidence of failed reperfusion or
reocclusion after fibrinolytic therapy. Angiography can be per-
formed as soon as logistically feasible (346,355–357). (Level
of Evidence: B)
Coronary angiography is reasonable before hospital discharge
in stable§ patients with STEMI after successful fibrinolytic
therapy. Angiography can be performed as soon as logistically
feasible, and ideally within 24 hours, but should not be per-
formed within the first 2 to 3 hours after administration of
fibrinolytic therapy (358–363,374). (Level of Evidence: B)
The indications for coronary angiography in patients man-
ed with an initial noninvasive strategy are interwoven with
e indications for revascularization (Sections 5.3 and 6.2).
urvivors of STEMI with indicators of intermediate or high
sk and those with recurrent ischemia or mechanical com-
ications should be considered for coronary angiography and
vascularization. In addition, when STEMI is suspected to
ve occurred by a mechanism other than thrombotic occlu-
lthough individual circumstances will vary, clinical stability is defined by the
sence of low output, hypotension, persistent tachycardia, apparent shock, high-
ade ventricular or symptomatic supraventricular tachyarrhythmias, and spontane-
ble 9. Indications for Coronary Angiography in Patients
ho Were Managed With Fibrinolytic Therapy or Who Did Not
eceive Reperfusion Therapy
COR LOE References
rdiogenic shock or acute severe HF that
velops after initial presentation
I B (215,354,
372,373)
termediate- or high-risk findings on
edischarge noninvasive ischemia testing
I B (232,233)
ontaneous or easily provoked myocardial
hemia
I C N/A
iled reperfusion or reocclusion after
rinolytic therapy
IIa B (346,355–357)
able* patients after successful fibrinolysis,
fore discharge and ideally between 3 and
h
IIa B (358–363,374)
*Although individual circumstances will vary, clinical stability is defined by
e absence of low output, hypotension, persistent tachycardia, apparent
ock, high-grade ventricular or symptomatic supraventricular tachyarrhyth-
ias, and spontaneous recurrent ischemia.
COR indicates Class of Recommendation; HF, heart failure; LOE, Level of
idence; and N/A, not available.fos recurrent ischemia.on at the site of an atherosclerotic plaque, coronary angiog-
phy may be reasonable to provide diagnostic information
d to direct specific therapy. Routine referral for angiogra-
y of patients after fibrinolytic therapy is discussed in
ection 5.3. Coronary angiography in patients with evidence
failed reperfusion or reocclusion should be performed as
on as logistically feasible (346,355).
.2. PCI of an Infarct Artery in Patients Who
itially Were Managed With Fibrinolysis or
ho Did Not Receive Reperfusion Therapy:
ecommendations
ee Table 10 for a summary of recommendations from this
ction.
ASS I
PCI of an anatomically significant stenosis in the infarct artery
should be performed in patients with suitable anatomy and any
of the following:
a. Cardiogenic shock or acute severe HF (354) (Level of
Evidence: B);
b. Intermediate- or high-risk findings on predischarge noninvasive
ischemia testing (232,233) (Level of Evidence: C); or
c. Myocardial ischemia that is spontaneous or provoked by
minimal exertion during hospitalization. (Level of Evidence: C)
ASS IIa
Delayed PCI is reasonable in patients with STEMI and evidence
of failed reperfusion or reocclusion after fibrinolytic therapy.
PCI can be performed as soon as logistically feasible at the
receiving hospital (344–347). (Level of Evidence: B)
Delayed PCI of a significant stenosis in a patent infarct artery
is reasonable in stable§ patients with STEMI after fibrinolytic
therapy. PCI can be performed as soon as logistically feasible
at the receiving hospital, and ideally within 24 hours, but
should not be performed within the first 2 to 3 hours after
administration of fibrinolytic therapy (358–363). (Level of
Evidence: B)
ASS IIb
Delayed PCI of a significant stenosis in a patent infarct artery
greater than 24 hours after STEMI may be considered as part
of an invasive strategy in stable§ patients (213,232,233,366,
374–378). (Level of Evidence: B)
ASS III: NO BENEFIT
Delayed PCI of a totally occluded infarct artery greater than 24
hours after STEMI should not be performed in asymptomatic
patients with 1- or 2-vessel disease if they are hemodynami-
cally and electrically stable and do not have evidence of severe
ischemia (213,376). (Level of Evidence: B)
Delayed PCI of the infarct artery is performed in patients
eated with an initial noninvasive strategy (i.e., with fibrino-
sis or without reperfusion therapy) who become unstable
cause of the development of cardiogenic shock, acute
vere HF, or unstable postinfarction angina, provided that
vasive management is not considered futile or inappropriate
15,379). Delayed PCI also encompasses interventions per-
rmed for fibrinolytic failure (355,356) or infarct artery
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ccessful fibrinolysis (359–361), and for patients who did
t receive reperfusion therapy but who did demonstrate
gnificant residual ischemia during hospitalization. The ben-
ts of routine, i.e., non–ischemia-driven, PCI of an angio-
aphically significant stenosis in a patent infarct artery 24
urs after STEMI are less well established (232,233,378).
elayed PCI of a totally occluded infarct artery 24 hours
ter STEMI should not be undertaken in clinically stable
tients without evidence of severe ischemia. In OAT (Oc-
uded Artery Trial), there was no difference in the composite
dpoint of death, reinfarction, or class IV HF at a median
llow-up of 5.8 years between patients managed with PCI
d those treated medically. Reinfarction rates tended to be
gher in the PCI group (380).
.3. PCI of a Noninfarct Artery Before
ospital Discharge: Recommendations
ASS I
PCI is indicated in a noninfarct artery at a time separate from
primary PCI in patients who have spontaneous symptoms of
myocardial ischemia. (Level of Evidence: C)
ASS IIa
PCI is reasonable in a noninfarct artery at a time separate from
primary PCI in patients with intermediate- or high-risk findings
on noninvasive testing (216,232,233). (Level of Evidence: B)
ultivessel coronary artery disease is present in 40% to 65%
patients presenting with STEMI who undergo primary PCI
d is associated with adverse prognosis (381,382). Studies
staged PCI of noninfarct arteries have been nonrandomized
design and have varied with regard to the timing of PCI and
ration of follow-up. These variations have contributed to
e disparate findings reported, although there seems to be a
ear trend toward lower rates of adverse outcomes when
imary PCI is limited to the infarct artery and PCI of a
ninfarct artery is undertaken in staged fashion at a later
me (216,224,225,383,384). The largest of these observa-
onal studies compared 538 patients undergoing staged
ultivessel PCI within 60 days of primary PCI with
opensity-matched individuals who had culprit-vessel PCI
ble 10. Indications for PCI of an Infarct Artery in Patients Wh
eperfusion Therapy
rdiogenic shock or acute severe HF
termediate- or high-risk findings on predischarge noninvasive ischemia testin
ontaneous or easily provoked myocardial ischemia
tients with evidence of failed reperfusion or reocclusion after fibrinolytic ther
able* patients after successful fibrinolysis, ideally between 3 and 24 h
able* patients 24 h after successful fibrinolysis
layed PCI of a totally occluded infarct artery 24 h after STEMI in stable pa
*Although individual circumstances will vary, clinical stability is defined by
gh-grade ventricular or symptomatic supraventricular tachyarrhythmias, and s
COR indicates Class of Recommendation; HF, heart failure; LOE, Level of E
-elevation myocardial infarction.one (216). Multivessel PCI was associated with a lowerortality rate at 1 year (1.3% versus 3.3%; p0.04). A
nsignificant trend toward a lower mortality rate at 1 year
as observed in the subset of 258 patients who underwent
aged PCI during the initial hospitalization for STEMI (216).
lthough fractional flow reserve is evaluated infrequently in
tients with STEMI, at least 1 study suggests that determi-
tion of fractional flow reserve may be useful to assess the
modynamic significance of potential target lesions in non-
farct arteries (385). The writing committee encourages
search into the benefit of PCI of noninfarct arteries in
tients with multivessel disease after successful primary PCI
ection 12.6).
.4. Adjunctive Antithrombotic Therapy to
upport Delayed PCI After Fibrinolytic
herapy
ee Table 11 for a summary of recommendations from this
ction.
The selection of adjunctive antiplatelet and anticoagulant
erapies for use during PCI after fibrinolytic therapy should
ke into account the fibrinolytic agent used, the time since its
ministration, and the antiplatelet and anticoagulant
ents already administered. GP IIb/IIIa inhibitors should
used with great caution, if at all, after full-dose
brinolytic therapy, because this combination is associated
ith high rates of bleeding and ICH, particularly in the
derly (386 –388,389).
.4.1. Antiplatelet Therapy to Support PCI After
ibrinolytic Therapy: Recommendations
ASS I
After PCI, aspirin should be continued indefinitely (253,254,257,
259,330,331). (Level of Evidence: A)
Clopidogrel should be provided as follows:
a. A 300-mg loading dose should be given before or at the
time of PCI to patients who did not receive a previous
loading dose and who are undergoing PCI within 24 hours
of receiving fibrinolytic therapy (Level of Evidence: C);
b. A 600-mg loading dose should be given before or at the
time of PCI to patients who did not receive a previous
Managed With Fibrinolytic Therapy or Who Did Not Receive
COR LOE References
I B (354)
I C (232,233)
I C N/A
soon as possible) IIa B (344–347)
IIa B (358–363)
IIb B (213,232,233,366,374–378)
III: No Benefit B (213,376)
ence of low output, hypotension, persistent tachycardia, apparent shock,
ous recurrent ischemia.
; N/A, not available; PCI, percutaneous coronary intervention; and STEMI,o Were
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C); and
c. A dose of 75 mg daily should be given after PCI (260,
262,330,331). (Level of Evidence: C)
ASS IIa
After PCI, it is reasonable to use 81 mg of aspirin per day in
preference to higher maintenance doses (253,259,263,264).
(Level of Evidence: B)
Prasugrel, in a 60-mg loading dose, is reasonable once the
coronary anatomy is known in patients who did not receive a
previous loading dose of clopidogrel at the time of administra-
tion of a fibrinolytic agent, but prasugrel should not be given
ble 11. Adjunctive Antithrombotic Therapy to Support PCI Afte
tiplatelet therapy
pirin
● 162- to 325-mg loading dose given with fibrinolytic agent (before PCI). (Se
5.1.4.1 and Table 7)
● 81- to 325-mg daily maintenance dose after PCI (indefinite)
● 81 mg daily is the preferred daily maintenance dose
Y12 receptor inhibitors
Loading doses
r patients who received a loading dose of clopidogrel with fibrinolytic therap
● Continue clopidogrel 75 mg daily without an additional loading dose
r patients who have not received a loading dose of clopidogrel:
● If PCI is performed 24 h after fibrinolytic therapy: clopidogrel 300-mg lo
dose before or at the time of PCI
● If PCI is performed 24 h after fibrinolytic therapy: clopidogrel 600-mg lo
dose before or at the time of PCI
● If PCI is performed 24 h after treatment with a fibrin-specific agent or 
after a non–fibrin-specific agent: prasugrel 60 mg at the time of PCI
r patients with prior stroke/TIA: prasugrel
Maintenance doses and duration of therapy
S placed: Continue therapy for at least 1 y with:
● Clopidogrel: 75 mg daily
● Prasugrel: 10 mg daily
S* placed: Continue therapy for at least 30 d and up to 1 y with:
● Clopidogrel: 75 mg daily
● Prasugrel: 10 mg daily
ticoagulant therapy
● Continue UFH through PCI, administering additional IV boluses as needed t
maintain therapeutic ACT depending on use of GP IIb/IIIa receptor antagoni
● Continue enoxaparin through PCI:
● No additional drug if last dose was within previous 8 h
● 0.3-mg/kg IV bolus if last dose was 8 to 12 h earlier
● Fondaparinux:
● As sole anticoagulant for PCI
*Balloon angioplasty without stent placement may be used in selected patien
dergoing balloon angioplasty after fibrinolysis alone according to the recomm
†The recommended ACT with no planned GP IIb/IIIa receptor antagonist trea
ACT indicates activated clotting time; BMS, bare-metal stent; COR, Class of Re
Evidence; N/A, not available; PCI, percutaneous coronary intervention; TIA, trsooner than 24 hours after administration of a fibrin-specific doagent or 48 hours after administration of a non–fibrin-specific
agent (260,262). (Level of Evidence: B)
Prasugrel, in a 10-mg daily maintenance dose, is reasonable
after PCI (260,262). (Level of Evidence: B)
ASS III: HARM
Prasugrel should not be administered to patients with a history
of prior stroke or transient ischemic attack (260). (Level of
Evidence: B)
atients with STEMI should receive clopidogrel at the time of
ministration of a fibrinolytic agent as a routine part of a
armacological reperfusion strategy (Section 5.1). Clopi-
nolytic Therapy
COR LOE References
I A (308,330,331)
I A (253,254,257,259,
330,331)
IIa B (253,259,263,264)
I C (260,262,330,331)
I C N/A
I C N/A
IIa B (260,262)
III:
Harm
B (260)
I C (260,262,330,331)
IIa B (260,262)
I C (330,331)
IIa B (260,262)
I C N/A
I B (332,390)
III:
Harm
C (304)
ght be reasonable to provide P2Y12 inhibitor therapy to patients with STEMI
ns listed for BMS. (Level of Evidence: C)
250–300 s (HemoTec device) or 300–350 s (Hemochron device).
dation; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; LOE, Level
ischemic attack; and UFH, unfractionated heparin.r Fibri
ction
y:
ading
ading
48 h
o
st†
ts. It mi
endatio
tment is
commengrel then should be continued in uninterrupted fashion
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grel before or at the time of PCI in patients who may not
ve received it previously with fibrinolytic therapy is not
own. In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive
eperfusion Therapy—Thrombolysis In Myocardial Infarction
) trial (331), PCI was performed 2 to 8 days after fibrinolysis
about half of the enrolled patients, and open-label clopidogrel
00-mg loading dose, 75-mg maintenance dose) was adminis-
red after diagnostic angiography in patients undergoing infarct
tery stenting. Treatment with clopidogrel significantly reduced
e incidence of cardiovascular death, MI, or stroke (major
condary composite endpoint) after PCI. In addition, there was
significant increase in the rates of TIMI major or minor
eeding with clopidogrel treatment. A subset of patients with
TEMI in the TRITON-TIMI 38 trial received fibrinolytic
erapy24 hours (for fibrin-specific agents) or48 hours (for
n–fibrin-specific agents) before PCI. In this subset, the use of
asugrel compared to clopidogrel was associated with a signif-
antly lower rate of the primary composite endpoint of cardio-
scular death, nonfatal MI, or nonfatal stroke (HR: 0.65; 95%
I: 0.54 to 0.87; p0.0017), and a similar rate of TIMI major
eeding unrelated to CABG (262). Accordingly, prasugrel
0-mg loading dose) may be used as an alternative to clopidogrel
patients with STEMI who undergo delayed PCI after adminis-
ation of a fibrinolytic agent.
.4.2. Anticoagulant Therapy to Support PCI After
ibrinolytic Therapy: Recommendations
ASS I
For patients with STEMI undergoing PCI after receiving fibrino-
lytic therapy with intravenous UFH, additional boluses of intra-
venous UFH should be administered as needed to support the
procedure, taking into account whether GP IIb/IIIa receptor
antagonists have been administered. (Level of Evidence: C)
For patients with STEMI undergoing PCI after receiving fibrino-
lytic therapy with enoxaparin, if the last subcutaneous dose
was administered within the prior 8 hours, no additional
enoxaparin should be given; if the last subcutaneous dose was
administered between 8 and 12 hours earlier, enoxaparin 0.3
mg/kg IV should be given (335,390). (Level of Evidence: B)
ASS III: HARM
Fondaparinux should not be used as the sole anticoagulant to
support PCI. An additional anticoagulant with anti-IIa activity
should be administered because of the risk of catheter
thrombosis (304). (Level of Evidence: C)
nticoagulation should be continued through emergent or
nurgent PCI procedures performed during the index hospital-
ation after initial use of fibrinolytic therapy. For patients who
ceived UFH or enoxaparin with fibrinolytic therapy, these
ents may be continued uninterrupted through the PCI proce-
re (390). Transitioning from enoxaparin to either UFH or
valirudin is possible, provided the last enoxaparin dose was
12 hours before PCI. Similarly, UFH may be transitioned to
valirudin for PCI. Fondaparinux does not provide adequate
ticoagulation for PCI, and additional intravenous boluses of UFH
r bivalirudin) should be administered (304).. Coronary Artery Bypass Graft Surgery
.1. CABG in Patients With STEMI:
ecommendations
ASS I
Urgent CABG is indicated in patients with STEMI and coronary
anatomy not amenable to PCI who have ongoing or recurrent
ischemia, cardiogenic shock, severe HF, or other high-risk
features (391–393). (Level of Evidence: B)
CABG is recommended in patients with STEMI at time of
operative repair of mechanical defects (394–398). (Level of
Evidence: B)
ASS IIa
The use of mechanical circulatory support is reasonable in
patients with STEMI who are hemodynamically unstable and
require urgent CABG. (Level of Evidence: C)
ASS IIb
Emergency CABG within 6 hours of symptom onset may be
considered in patients with STEMI who do not have cardiogenic
shock and are not candidates for PCI or fibrinolytic therapy.
(Level of Evidence: C)
ABG has a limited role in the acute phase of STEMI other
an for cardiogenic shock, but it may be indicated for failed
CI, for coronary anatomy not amenable to PCI, and at the
me of surgical repair of a mechanical defect, such as
ntricular septal, papillary muscle, or free-wall rupture.
lder case series highlighted a potential excess mortality risk
r CABG when performed early after STEMI, which was
lated to worsening myocardial injury from cardiopulmo-
ry bypass, aortic cross-clamping, and cardioplegic arrest,
ith hemorrhagic transformation and infarct expansion.
owever, contemporary modifications to the standard oper-
ive approach, such as on-pump beating-heart surgery, off-
mp techniques, or adjunctive temporary mechanical circu-
tory support devices, may lead to improved survival rates
ter CABG in the acute hospital phase.
.2. Timing of Urgent CABG in Patients With
TEMI in Relation to Use of Antiplatelet
gents: Recommendations
ASS I
Aspirin should not be withheld before urgent CABG (399).
(Level of Evidence: C)
Clopidogrel or ticagrelor should be discontinued at least 24
hours before urgent on-pump CABG, if possible (400–404).
(Level of Evidence: B)
Short-acting intravenous GP IIb/IIIa receptor antagonists (ep-
tifibatide, tirofiban) should be discontinued at least 2 to 4
hours before urgent CABG (405,406). (Level of Evidence: B)
Abciximab should be discontinued at least 12 hours before
urgent CABG (362). (Level of Evidence: B)
ASS IIb
Urgent off-pump CABG within 24 hours of clopidogrel or ticagre-
lor administration might be considered, especially if the bene-
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(401,407–409). (Level of Evidence: B)
Urgent CABG within 5 days of clopidogrel or ticagrelor admin-
istration or within 7 days of prasugrel administration might be
considered, especially if the benefits of prompt revasculariza-
tion outweigh the risks of bleeding. (Level of Evidence: C)
contrast to previous observations (410–412) of markedly
creased rates of major bleeding and mediastinal reex-
oration after CABG in patients exposed to clopidogrel
ithin 5 to 7 days before CABG, several reports have
ggested that it might be reasonable to proceed with urgent
rgery within a shorter time frame, especially when the
nefits of revascularization outweigh the risks of bleeding,
often may be the case among patients with ACS (402,404).
horter delays to urgent surgery may also be possible when
f-pump revascularization is planned. Among the 136 pa-
ents in CLARITY-TIMI 28 who underwent CABG within 5
ys of clopidogrel exposure, there was no difference in the
tes of major bleeding through 30 days of follow-up between
e clopidogrel and placebo groups (7.5% versus 7.2%,
spectively; p1.00) (331). In a prospective RCT examining
e effect of the timing of clopidogrel discontinuation before
ABG, 3 groups were studied: clopidogrel continued to the
y of surgery, clopidogrel discontinued 3 days before
rgery, and clopidogrel discontinued 5 days before surgery.
atients in the continuation group experienced increased rates
bleeding and blood product utilization, but the 3- and 5-day
scontinuation groups had comparably low bleeding rates
d blood product usage that resembled historical control
lues (413). In a retrospective analysis of a nonrandomized
bgroup of patients in the PLATO trial, in which several
finitions of bleeding were used, no significant differences in
ABG-related bleeding were observed between patients al-
cated ticagrelor and patients who received clopidogrel, and
ere were no observed differences in the rates of reoperation
01). In contrast, among the relatively few patients with
TEMI in TRITON-TIMI 38 who underwent CABG during
e 15-month course of the study, rates of TIMI major or
inor bleeding after CABG were significantly higher with
asugrel than with clopidogrel (21.9% versus 4.1%; OR:
53; 95% CI: 1.78 to 23.94; p0.0032) (262). The excess
eeding hazard observed with prasugrel should prompt
nsideration of an alternative antiplatelet strategy in patients
ith STEMI who may require urgent CABG during their
dex hospitalization. The timing of elective CABG in rela-
on to the use of P2Y12 receptor antagonists is referenced in
ection 4.1 of the 2011 ACCF/AHA Guideline for Coronary
rtery Bypass Graft Surgery (393).
. Routine Medical Therapies
ee Table 12 for a summary of selected routine medical
erapies.
.1. Beta Blockers: Recommendations
ASS I
Oral beta blockers should be initiated in the first 24 hours in
patients with STEMI who do not have any of the following: timsigns of HF, evidence of a low output state, increased risk for
cardiogenic shock, or other contraindications to use of oral
beta blockers (PR interval more than 0.24 seconds, second- or
third-degree heart block, active asthma, or reactive airways
disease) (414–416). (Level of Evidence: B)
Beta blockers should be continued during and after hospital-
ization for all patients with STEMI and with no contraindica-
tions to their use (417,418). (Level of Evidence: B)
Patients with initial contraindications to the use of beta
blockers in the first 24 hours after STEMI should be reeval-
uated to determine their subsequent eligibility. (Level of
Evidence: C)
ASS IIa
It is reasonable to administer intravenous beta blockers at the
time of presentation to patients with STEMI and no contrain-
dications to their use who are hypertensive or have ongoing
ischemia (414–416). (Level of Evidence: B)
he efficacy and safety of the early routine use of intravenous
ta blockers were examined in COMMIT/CCS-2 (Clopi-
grel and Metoprolol in Myocardial Infarction Trial) (414).
arly intravenous metoprolol followed by high-dose oral
erapy had a neutral effect on the combined endpoint of
ath, recurrent MI, or cardiac arrest. There were lower rates
recurrent MI and VF in the treated group, outcomes that
ere balanced by a significantly higher rate of cardiogenic
ock with metoprolol, especially on days 0 and 1. The
kelihood of developing cardiogenic shock was increased in
rtain subgroups, including patients with age 70 years,
stolic BP 120 mm Hg, presenting heart rate 110 bpm,
increased time since onset of symptoms of STEMI. The
nefit of beta blockers for secondary prevention has been
tablished in numerous trials conducted in the prereperfu-
on era and appears to be greatest for patients with MI
mplicated by HF, LV dysfunction, or ventricular arrhyth
ias (418). The long-term duration of routine beta-blocker
erapy after uncomplicated MI in patients without HF or
pertension has not been prospectively addressed. AHA/
CCF secondary prevention guidelines recommend a 3-year
eatment course in this patient subset (257).
.2. Renin-Angiotensin-Aldosterone System
hibitors: Recommendations
ASS I
An angiotensin-converting enzyme (ACE) inhibitor should be
administered within the first 24 hours to all patients with
STEMI with anterior location, HF, or ejection fraction (EF) less
than or equal to 0.40, unless contraindicated (420–423).
(Level of Evidence: A)
An angiotensin receptor blocker (ARB) should be given to
patients with STEMI who have indications for but are intolerant
of ACE inhibitors (424,425). (Level of Evidence: B)
An aldosterone antagonist should be given to patients with
STEMI and no contraindications who are already receiving an
isk factors for cardiogenic shock (the greater the number of risk factors present,
e higher the risk of developing cardiogenic shock) are age 70 years, systolic BP
120 mm Hg, sinus tachycardia 110 bpm or heart rate 60 bpm, and increasede since onset of symptoms of STEMI.
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equal to 0.40 and either symptomatic HF or diabetes mellitus
(426). (Level of Evidence: B)
ASS IIa
ACE inhibitors are reasonable for all patients with STEMI and
no contraindications to their use (427–429). (Level of
ble 12. Selected Routine Medical Therapies
Therapy Indications
ta-Receptor
tagonists
● Oral: All patients without
contraindication
● IV: Patients with refractory hypertension
or ongoing ischemia without
contraindication
Indi
● M
6
ne
m
m
do
● Ca
to
● M
m
to
E Inhibitors ● For patients with anterior infarction,
post-MI LV systolic dysfunction (EF 
0.40) or HF
● May be given routinely to all patients
without contraindication
Indi
● Li
tit
to
● Ca
to
tim
● Ra
tit
● Tr
up
B ● For patients intolerant of ACE inhibitors ● Va
tit
to
atins ● All patients without contraindications ● Hi
troglycerin ● Ongoing chest pain
● Hypertension and HF
● 0.
3
● IV
tit
ygen ● Clinically significant hypoxemia (oxygen
saturation 90%)
● HF
● Dyspnea
● 2
● In
as
orphine ● Pain
● Anxiety
● Pulmonary edema
● 4
do
● 2
ne
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor block
L, high-density lipoprotein; HF, heart failure; IV, intravenous; LDL, low-densit
P, systolic blood pressure.Evidence: A) beral ACE inhibitors reduce fatal and nonfatal major cardiovascular
ents in patients with STEMI (360,361,420,422,428–430). Their
otective effects have been demonstrated independent of the
e of other pharmacotherapies (i.e., fibrinolytics, aspirin, and
ta blockers). The magnitude of clinical benefit is greatest in
gh-risk patient subgroups (i.e., anterior MI, EF 0.40, HF,
ior MI, and tachycardia) (431). Demonstration of an early
ose/Administration Avoid/Caution
:
l tartrate 25 to 50 mg every
orally, then transition over
3 d to twice-daily dosing of
l tartrate or to daily
l succinate; titrate to daily
00 mg as tolerated
6.25 mg twice daily, titrate
wice daily as tolerated
l tartrate IV 5 mg every 5
lerated up to 3 doses; titrate
te and BP
● Signs of HF
● Low output state
● Increased risk of cardiogenic shock
● Prolonged first-degree or high-grade
AV block
● Reactive airways disease
:
2.5 to 5 mg/d to start;
0 mg/d or higher as
6.25 to 12.5 mg 3 times/d
trate to 25 to 50 mg 3
tolerated
.5 mg twice daily to start;
mg twice daily as tolerated
ril test dose 0.5 mg; titrate
g daily as tolerated
● Hypotension
● Renal failure
● Hyperkalemia
20 mg twice daily to start;
60 mg twice daily as
● Hypotension
● Renal failure
● Hyperkalemia
atorvastatin 80 mg daily ● Caution with drugs metabolized via
CYP3A4, fibrates
● Monitor for myopathy, hepatic
toxicity
● Combine with diet and lifestyle
therapies
● Adjust dose as dictated by targets
for LDL cholesterol and non–HDL
cholesterol reduction
blingual every 5 min up to
s BP allows
to begin at 10 mcg/min;
esired BP effect
● Avoid in suspected RV infarction
● Avoid with SBP 90 mm Hg or if
SBP 30 mm Hg below baseline
● Avoid if recent (24 to 48 h) use of
5=-phosphodiesterase inhibitors
in via nasal cannula
ate or change to face mask
● Caution with chronic obstructive
pulmonary disease and CO2
retention
IV initially, with lower
lderly
IV every 5 to 15 min if
● Lethargic or moribund patient
● Hypotension
● Bradycardia
● Known hypersensitivity
trioventricular; BP, blood pressure; CO2, carbon dioxide; EF, ejection fraction;
tein; LV, left ventricular; MI, myocardial infarction; RV, right ventricular; andD
vidualize
etoprolo
to 12 h
xt 2 to
etoprolo
etoprolo
se of 2
rvedilol
25 mg t
etoprolo
in as to
heart ra
vidualize
sinopril
rate to1
lerated
ptopril
start; ti
es/d as
mipril 2
rate to5
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to 4 m
lsartan
rate to 1
lerated
gh-dose
4 mg su
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ypotension, shock, bilateral renal artery stenosis or history
worsening of renal function with ACE inhibitor/ARB
posure, renal failure, or drug allergy). The role of routine
ng-term ACE inhibitor therapy in low-risk patients after
TEMI who have been revascularized and treated with
gressive lipid-lowering therapies is less certain (432).
RBs are indicated for ACE inhibitor–intolerant patients.
pecifically, valsartan was found to be noninferior to capto-
il in the VALIANT (Valsartan in Acute Myocardial Infarc-
on) trial (424).
The EPHESUS (Eplerenone Post-Acute Myocardial In-
rction Heart Failure Efficacy and Survival) study estab-
shed the benefit of an aldosterone antagonist, eplerenone,
ded to optimal medical therapy in eligible patients (creat-
ine 2.5 mg/dL in men and 2.0 mg/dL in women,
tassium 5.0 mEq/L) 3 to 14 days after STEMI with EF
0.40 and either symptomatic HF or diabetes mellitus (426).
post hoc analysis of the EPHESUS trial suggested a
me-dependent treatment effect of eplerenone. Earlier initia-
on of the drug (7 days) significantly reduced the rates of
l-cause mortality, sudden cardiac death (SCD), and cardio-
scular mortality/hospitalization, whereas initiation7 days
d no significant effect on outcomes (433).
.3. Lipid Management: Recommendations
ASS I
High-intensity statin therapy should be initiated or continued in
all patients with STEMI and no contraindications to its use
(434–436). (Level of Evidence: B)
ASS IIa
It is reasonable to obtain a fasting lipid profile in patients with
STEMI, preferably within 24 hours of presentation. (Level of
Evidence: C)
reatment with statins in patients stabilized after an ACS,
cluding STEMI, lowers the risk of coronary heart disease
ath, recurrent MI, stroke, and the need for coronary
vascularization (437,438). More intensive statin therapy,
mpared with less intensive therapy, appears to be associ-
ed with an additional lowering of nonfatal clinical end-
ints (434,436,439). Among currently available statins, only
gh-dose atorvastatin (80 mg daily) has been shown to
duce death and ischemic events among patients with ACS
36,440). Approximately one third of patients in the
ROVE-IT TIMI 22 (Pravastatin or Atorvastatin Evaluation
d Infection Therapy—Thrombolysis in Myocardial Infarc-
on 22) trial had STEMI (436). Cardiovascular event rates
ere not significantly reduced with a tiered strategy of
mvastatin (40-mg daily for 1 month followed by 80 mg
ily) in the A to Z Trial (Aggrastat to Zocor) (439), and
ncerns have been raised recently about the safety of
gh-dose simvastatin (i.e., 80 mg daily) (441). Although the
nefit of high-intensity statins declines among statin-naïve
tients with ACS as a function of decreasing low-density
poprotein levels (442), the writing committee recommends
e use of statins in all patients with STEMI (435). Statin
erapy after ACS is beneficial even in patients with baseline diw-density lipoprotein cholesterol levels 70 mg/dL (443).
rials of statin therapy in patients with ACS and stable
chemic heart disease have been designed to compare either
ore intensive versus less intensive statin treatment or active
atin versus placebo (434–440). They have not been de-
gned to compare clinical outcomes as a function of the
ecific low-density lipoprotein cholesterol level achieved
ith treatment. Improved compliance with therapy is a strong
tionale for timing the initiation of lipid-lowering drug
erapy before discharge after STEMI. Longer-term lipid
anagement after STEMI, including indications for targeting
iglycerides and non–high-density lipoprotein cholesterol,
e addressed in the “AHA/ACC Secondary Prevention and
isk Reduction Therapy for Patients With Coronary and
ther Vascular Disease: 2011 Update” (257).
.4. Nitrates
lthough nitroglycerin can ameliorate symptoms and signs of
yocardial ischemia by reducing LV preload and increasing
ronary blood flow, it generally does not attenuate the
yocardial injury associated with epicardial coronary artery
clusion unless vasospasm plays a significant role. Intrave-
us nitroglycerin may be useful to treat patients with STEMI
d hypertension or HF. Nitrates should not be given to
tients with hypotension, marked bradycardia or tachycar-
a, RV infarction, or 5=phosphodiesterase inhibitor use
ithin the previous 24 to 48 hours (444). There is no role for
e routine use of oral nitrates in the convalescent phase of
TEMI.
.5. Calcium Channel Blockers
n overview of 28 RCTs involving 19,000 patients demon-
rated no beneficial effect on infarct size or the rate of
infarction when calcium channel blocker therapy was ini-
ated during either the acute or convalescent phase of STEMI
45). Calcium channel blockers may be useful, however, to
lieve ischemia, lower BP, or control the ventricular re-
onse rate to atrial fibrillation (AF) in patients who are
tolerant of beta blockers. Caution is advised in patients with
V systolic dysfunction. The use of the immediate-release
fedipine is contraindicated in patients with STEMI because
hypotension and reflex sympathetic activation with tachy-
rdia (446).
.6. Oxygen
ew data exist to support or refute the value of the routine use
oxygen in the acute phase of STEMI, and more research is
eded. A pooled Cochrane analysis of 3 trials showed a
fold higher risk of death for patients with confirmed acute
I treated with oxygen than for patients with acute MI
anaged on room air. Oxygen therapy is appropriate for
tients who are hypoxemic (oxygen saturation 90%) and
ay have a salutary placebo effect in others. Supplementary
ygen may, however, increase coronary vascular resistance
47). Oxygen should be administered with caution to pa-
ents with chronic obstructive pulmonary disease and carbon
oxide retention.
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onsteroidal Anti-Inflammatory Drugs,
nd Cyclooxygenase II Inhibitors
the absence of a history of hypersensitivity, morphine
lfate is the drug of choice for pain relief in patients with
TEMI, especially those whose course is complicated by
ute pulmonary edema. It can alleviate the work of breath-
g, reduce anxiety, and favorably affect ventricular loading
nditions. The dose of morphine sulfate needed to achieve
equate pain control will vary depending on patient age,
dy size, BP, and heart rate. Naloxone can be administered
doses of 0.1 to 0.2 mg IV every 15 minutes when indicated
reverse the narcotic effects of morphine, and atropine 0.5 to
5 mg IV may be administered to counter excessive
orphine-related bradycardia.
Epidemiological studies and retrospective analyses of
CTs have suggested that nonsteroidal anti-inflammatory
ugs and selective cyclooxygenase II enzyme (COX-2)
hibitors may be associated with an increased risk of death,
infarction, cardiac rupture, hypertension, renal insuffi-
ency, and HF (448–451). Nonsteroidal anti-inflammatory
ugs and COX-2 inhibitors are contraindicated in patients
ith STEMI. They should not be initiated in the acute phase
d should be discontinued in patients using them before
spitalization.
. Complications After STEMI
.1. Cardiogenic Shock
.1.1. Treatment of Cardiogenic Shock:
ecommendations
ASS I
Emergency revascularization with either PCI or CABG is rec-
ommended in suitable patients with cardiogenic shock due to
pump failure after STEMI irrespective of the time delay from MI
onset (212,379,452). (Level of Evidence: B)
In the absence of contraindications, fibrinolytic therapy should
be administered to patients with STEMI and cardiogenic shock
who are unsuitable candidates for either PCI or CABG
(81,453,454). (Level of Evidence: B)
ASS IIa
The use of intra-aortic balloon pump (IABP) counterpulsation
can be useful for patients with cardiogenic shock after STEMI
who do not quickly stabilize with pharmacological therapy
(455–459). (Level of Evidence: B)
ASS IIb
Alternative LV assist devices for circulatory support may be
considered in patients with refractory cardiogenic shock.
(Level of Evidence: C)
ardiogenic shock in patients with STEMI may be caused by
tensive LV infarction or by mechanical complications,
cluding papillary muscle rupture, ventricular septal rupture,
ee-wall rupture with tamponade, and RV infarction. The
set of cardiogenic shock due to mechanical complications
ter STEMI is bimodal; most cases occur within 24 hours. anor those with pump failure, 15% of cases occur at time of
esentation, and 85% develop during hospitalization. Revas-
larization with timely PCI or CABG is the preferred
perfusion strategy for patients with STEMI and shock due
pump failure, irrespective of the time delay. Shock or
vere HF is perhaps the only clinical scenario in which acute
vascularization of significant stenoses in noninfarct arteries
n be justified. In the SHOCK trial, mortality rates at 6 and
months were significantly lower in patients allocated to
ergency revascularization than in patients who received
mediate medical stabilization (212,354). Nearly two thirds
the patients in the medical stabilization group received
brinolytic therapy, and 25% underwent delayed revascular-
ation. IABP support was used in 86% of both groups.
lthough the trial did not show benefit with emergency
vascularization for the prespecified age group 75 years,
e small number of patients in the trial did not allow for firm
nclusions to be drawn about management. Elderly patients
fered emergency revascularization in the nonrandomized
HOCK registry had a substantial adjusted survival benefit
ith emergency revascularization compared with delayed or
revascularization (460). Similar findings in favor of early
vascularization for selected elderly patients were reported
om 2 additional registries (461,462). Although age alone is
t a contraindication to emergency revascularization in this
tting, individual judgment based on comorbidities, func-
onal status, and patient directives is necessary in the elderly.
riage and immediate transfer to a PCI-capable facility with
-site cardiac surgical backup are indicated for patients with
TEMI complicated by shock. Fibrinolytic therapy is re-
rved for patients without contraindications within 24 hours
MI for whom revascularization is considered not feasible
r technical, anatomic, or patient-related issues. The need for
modynamic support with inotropic therapy, IABP, or both
ould be assessed on an individual basis. Observational data
the usefulness of IABP in this setting are conflicting. A
eta-analysis supports IABP therapy as an adjunct to fibri-
lysis but not to primary PCI (458). Compared with IABP,
V assist devices may provide superior hemodynamic sup-
rt and serve as more effective bridges to recovery or
ansplantation, though experience with their use in this
tting is limited (463,464). Medical support with inotropes
d vasopressor agents should be individualized and guided
invasive hemodynamic monitoring. Use of dopamine in
is setting may be associated with excess hazard (465).
.2. Severe HF
he development of HF after STEMI is an indication for
giography with intent to proceed with revascularization if
t previously performed. LV myocardium may be ischemic,
unned, hibernating, or irrevocably injured, and viability
sessment may be needed depending on the timing of
vascularization. Ischemic (functional) mitral regurgitation
e to LV remodeling may coexist, progress over time, and
quire surgical attention depending on its severity. Medical
eatment is based on the use of diuretics, vasodilators, and
otropic agents when required. Inhibitors of the renin-
giotensin-aldosterone system should be provided as toler-
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aluated continuously throughout the hospital course.
.3. RV Infarction
V infarction complicates the course of approximately one
ird of patients with inferior STEMI, is most often due to
oximal occlusion of the right coronary artery, and is
sociated with a higher mortality risk. Evidence of RV
volvement should be sought in all patients with inferior
TEMI. The clinical triad of hypotension, clear lung fields,
d elevated jugular venous pressure is characteristic. Dem-
stration of 1-mm ST elevation in lead V1 and in right
ecordial lead V4R is the most sensitive ECG marker of RV
jury (466). Transthoracic echocardiography can be helpful
patients with initially nondiagnostic findings (467). Treat-
ent includes maintenance of RV preload, reduction of RV
terload, inotropic support if needed, and immediate reper-
sion (468,469). Nitrates and diuretics should be avoided.
estoration of atrioventricular (AV) synchrony or cardiover-
on from AF may be needed.
.4. Mechanical Complications
.4.1. Diagnosis
echanical complications after STEMI have a bimodal,
mporal distribution: Most occur in the first 24 hours, and the
mainder present within the first week. The presence of a
w systolic murmur indicates the possibility of either ven-
icle septal rupture or mitral regurgitation. Diagnosis usually
n be established with transthoracic echocardiography. Sur-
cal consultation should be obtained when a mechanical
fect is suspected. Prompt repair (with or without CABG) is
dicated in most cases. IABP can provide temporary circu-
tory support.
.4.2. Mitral Regurgitation
itral regurgitation after STEMI occurs via 1 of 2 mecha-
sms: papillary muscle rupture or postinfarction LV remod-
ing with displacement of the papillary muscles, leaflet
thering, and annular dilatation. Acute rupture affects the
steromedial papillary muscle more often than anterolateral
pillary muscle because of its singular blood supply
70,471). Acute severe mitral regurgitation is characterized
pulmonary edema and/or shock; a systolic murmur may
t always be appreciated. Suitable patients with papillary
uscle rupture should be considered for urgent surgery while
mporary stabilization with medical therapy and IABP is
tempted. Mitral valve replacement rather than repair usually
required in this setting. Although emergency mitral valve
placement is associated with a relatively high mortality rate
0%), survival and ventricular function are improved with
rgery compared with medical therapy alone. Delay to
eration appears to increase the risk of further myocardial
jury, organ failure, and death (472). Five-year survival rates
ter surgery average 60% to 70% (397,473–476).
With ischemic (functional) mitral regurgitation, treatment
focused on timely reperfusion, diuretics, and afterload
duction. The severity of mitral regurgitation may improve
some patients with aggressive medical treatment, PCI, or
th. The rate of long-term survival after STEMI declines as anfunction of residual mitral regurgitation severity. If surgery
required during the index hospitalization because of ongo-
g ischemia or HF, mitral valve repair with a downsized
nuloplasty ring usually is performed, though valve replace-
ent may be preferred in many cases. In this regard,
anagement of ischemic mitral regurgitation differs impor-
ntly from that of myxomatous mitral regurgitation.
.4.3. Ventricular Septal Rupture
entricular septal rupture usually is heralded by a loud
stolic murmur and HF or shock, depending on the size of
e defect and the degree of RV and LV dysfunction. Data
om the GUSTO-1 (The Global Use of Strategies to Open
ccluded Coronary Arteries) trial and the SHOCK registry
dicate that ventricular septal rupture occurs most often
ithin the first 24 hours in patients with STEMI treated with
brinolytic therapy (477,478). Emergency surgical repair is
cessary, even in hemodynamically stable patients (479–
1), because the rupture site can expand abruptly, resulting
sudden hemodynamic collapse in previously stable patients
81). Temporizing medical treatment consists of inotropic
d vasodilator agents, with IABP when needed. The surgical
ortality rate remains high, especially among patients with
ock, ranging from 20% to 87% in reported series (395,477–
0,482,483). Mortality risk is higher for patients with
ferior-basal defects than for those with anterior-apical
fects. Percutaneous closure is a less invasive option that
ight allow for initial hemodynamic stabilization, but expe-
ence with this approach is limited, and residual shunts are
mmon. Further technical developments and prospective
ials are required to identify patients best suited for trans-
theter closure.
.4.4. LV Free-Wall Rupture
ree-wall rupture is characterized by recurrent chest pain and
T-T-wave changes, with rapid progression to hemodynamic
llapse, electromechanical dissociation, and death (484). It
observed most frequently in patients with first MI, anterior
farction, the elderly, and women. Other risk factors include
pertension during the acute phase of STEMI, lack of
tecedent angina or prior MI, absence of collateral blood
ow, Q waves on ECG, use of corticosteroids or nonsteroidal
ti-inflammatory drugs, and administration of fibrinolytic
erapy 14 hours after symptom onset (485,486). Pseudo-
eurysm formation with contained rupture and tamponade
n be recognized with transthoracic echocardiography, and
ergency surgery should be considered. Most case series of
tients reaching the operating room for management of this
mplication are of small size, with mortality rates approach-
g 60% (396,487).
.4.5. LV Aneurysm
entricular aneurysm formation after STEMI occurs in 5%
patients and is more frequent in those with anterior
farction. Incidence rates have declined with timely reper-
sion. Surgery for LV aneurysm after STEMI is rarely
eded but may be considered for treatment of HF, ventric-
ar arrhythmias not amenable to drugs or radiofrequency
lation, or recurrent thromboembolism despite appropriate
ticoagulant therapy.
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ospital Phase of STEMI
.5.1. Ventricular Arrhythmias
entricular arrhythmias are common early after onset of
TEMI, and not all require intervention. Out-of-hospital
rdiac arrest with STEMI is most often due to lethal
ntricular arrhythmias, including sustained VT and VF
ection 3.6.1). The mechanisms for these arrhythmias are
ultifactorial and include ongoing ischemia, hemodynamic
d electrolyte abnormalities, reentry, and enhanced automa-
city. As many as 10% of hospitalized patients receiving
brinolytic therapy in the GUSTO-I trial had sustained
T/VF complicating their course (488). An analysis of
tients referred for primary PCI in the APEX-AMI (Assess-
ent of Pexelizumab in Acute Myocardial Infarction) trial
ported a lower incidence of sustained VT/VF (5.7%); 90%
cases occurred within 48 hours of presentation (489).
ompared with patients without VT/VF, 90-day mortality
sk was 2-fold higher for patients with early VT/VF (i.e.,
fore the completion of primary PCI) and 5-fold higher for
tients with late VT/VF (i.e., after primary PCI). Several
ctors were associated with the occurrence of both early and
te VT/VF, including HF, hypotension, tachycardia, shock,
d TIMI flow grade. Treatment consists of immediate
fibrillation or cardioversion for VF or pulseless sustained
T, respectively, and antiarrhythmic drug therapy in accor-
nce with the 2010 Advanced Cardiac Life Support guide-
nes for sustained VT with a pulse (490). Prevention of
T/VF is directed to correction of electrolyte and acid/base
normalities, optimization of myocardial perfusion, eradica-
on of ongoing ischemia, and treatment of associated com-
ications such as HF or shock. Early (within 24 hours of
esentation) administration of beta blockers has been asso-
ated with a reduction in the incidence of VF (414,489) and
recommended for all patients without contraindications
ection 8.1). The prophylactic use of lidocaine is not
commended. Premature ventricular complexes, nonsus-
ined VT not associated with hemodynamic compromise,
d accelerated idioventricular rhythms that emerge after
perfusion are not indicative of increased SCD risk and do
t require specific therapy in the acute phase of STEMI.
.5.2. Implantable Cardioverter-Defibrillator Therapy
efore Discharge
ASS I
Implantable cardioverter-defibrillator (ICD) therapy is indicated
before discharge in patients who develop sustained VT/VF
more than 48 hours after STEMI, provided the arrhythmia is not
due to transient or reversible ischemia, reinfarction, or meta-
bolic abnormalities (491–493). (Level of Evidence: B)
ife-threatening ventricular arrhythmias that occur 48
urs after STEMI usually are associated with significant LV
stolic dysfunction and signify poor prognosis. Although
evious RCTs (492,494,495) have not specifically addressed
is population of patients with STEMI, they have shown
ear and consistent benefit of ICD therapy for survivors of
stained VT or VF arrest (493). In the absence of a inversible cause, late (48 hours) in-hospital sustained
T/VF is an indication for ICD therapy for secondary
evention of SCD. For other at-risk patients, particularly
ose with significantly reduced left ventricular ejection
action (LVEF), candidacy for ICD therapy for primary
evention of SCD should be reassessed at 40 days after
scharge (Section 10.3). See the “2008 ACCF/AHA/HRS
uidelines for Device-Based Therapy of Cardiac Rhythm
bnormalities” (496).
.5.3. AF and Other Supraventricular
achyarrhythmias
F, atrial flutter, and other supraventricular tachyarrhythmias
cur frequently in patients with STEMI and are triggered by
cessive sympathetic stimulation, atrial stretch due to LV or
V volume/pressure overload, atrial infarction, pericarditis,
ectrolyte abnormalities, hypoxia, or underlying lung dis-
se. By far the most common supraventricular arrhythmia is
F, which occurs in 8% to 22% of patients with STEMI, with
gher rates in elderly patients and those with HF and
pertension. In a contemporary study, the incidence of
w-onset AF during hospitalization was 6.3% (497). New-
set AF was significantly associated with shock, HF, stroke,
d 90-day mortality (497). These observations mirrored
ose seen in earlier trials (317,422,428,497–499). The cu-
ulative incidence of AF among MI survivors with EF0.40
er approximately 2 years of follow-up approaches 30%
00).
Management of AF during hospitalization for STEMI is
sed on the usual considerations of rhythm versus rate
ntrol and the indications for anticoagulation according to
rrent guidelines (501,502). For hemodynamically unstable
tients or those with ongoing ischemic symptoms, treatment
ould be implemented according to the 2010 Advanced
ardiac Life Support guideline for management of unstable
praventricular tachyarrhythmias (490). If medical treatment is
successful, synchronized, direct current cardioversion may be
dicated. Provision of anticoagulation in the context of DAPT
eates additional challenges related to the risk of bleeding
ection 9.7).
.5.4. Bradycardia, AV Block, and
traventricular Conduction Defects
.5.4.1. PACING IN STEMI: RECOMMENDATION
ASS I
Temporary pacing is indicated for symptomatic bradyarrhyth-
mias unresponsive to medical treatment. (Level of Evidence: C)
inus bradycardia is common early after STEMI, particularly
ith inferior location. It is mediated through increased vagal
ne, is usually self-limited, and generally requires no treat-
ent. It may be necessary to withhold beta blockers until the
adycardia resolves. Symptomatic or hemodynamically im-
rtant sinus bradycardia should be treated with atropine or
mporary pacing if not responsive (504).
The development of AV block and intraventricular con-
ction delays is associated with the extent of infarction. The
cidence of abnormal conduction has decreased substantially
the reperfusion era. In a survey of nearly 3 million hospital
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mplete heart block was 3.7% in inferior/posterior MI and
0% in anterior/lateral MI (505). AV block of varying degree
d persistent bundle-branch block develop in approximately
and 5% of patients with STEMI, respectively (506,507).
igh-grade (i.e., second- or third-degree) AV block and
rsistent bundle-branch block are independently associated
ith worse short- and long-term prognosis in both inferior/
sterior and anterior/lateral MI but are more ominous in
terior/lateral MI because of a relatively greater extent of
yocardial injury (506–508).
First-degree AV block does not require treatment. High-
ade AV block with inferior/posterior STEMI usually is
ansient and associated with a narrow complex/junctional
cape rhythm that can be managed conservatively. Applica-
on of transcutaneous pacing pads for potential use is
asonable. Prophylactic placement of a temporary pacing
stem is recommended for high-grade AV block and/or new
ndle-branch (especially LBBB) or bifascicular block in
tients with anterior/lateral MI. Choice of pacing system
ranscutaneous versus transvenous) varies across institutions.
dications for permanent pacing for persistent AV block or
ndle-branch block after STEMI are reviewed in the 2008
CC/AHA/HRS device-based therapy guidelines (496).
.6. Pericarditis
.6.1. Management of Pericarditis After STEMI:
ecommendations
ASS I
Aspirin is recommended for treatment of pericarditis after
STEMI (509). (Level of Evidence: B)
ASS IIb
Administration of acetaminophen, colchicine, or narcotic anal-
gesics may be reasonable if aspirin, even in higher doses, is not
effective. (Level of Evidence: C)
ASS III: HARM
Glucocorticoids and nonsteroidal anti-inflammatory drugs are
potentially harmful for treatment of pericarditis after STEMI
(510,511). (Level of Evidence: B)
he incidence of acute pericarditis after STEMI has de-
eased with the aggressive use of reperfusion therapy
12,513). Pericarditis should be considered in the differential
agnosis of recurrent chest pain after STEMI, particularly
hen the discomfort is pleuritic or positional, radiates to the
apezius ridge, and is associated with a pericardial friction
b. Recurrent or worsening ST elevation without early
-wave inversion may be present. Distinction from reinfarc-
on or acute stent thrombosis is crucial. In rare circum-
ances, if pain is persistent (1 week) and accompanied by
stemic features of malaise, fever, and increased inflamma-
ry biomarkers, Dressler syndrome should be considered. In
ost cases, the pain is self-limited and responds to conser-
tive measures. The use of colchicine has been extrapolated
om its efficacy in other settings. Although pericarditis is not
absolute contraindication to anticoagulation (514), caution vitould be exercised because of the potential for hemorrhagic
nversion (515).
Asymptomatic pericardial effusions are common after
TEMI (516,517). It is important to exclude free-wall rupture
hen a pericardial effusion is present (518,519), especially if
e width of the effusion is 1 cm (520). When tamponade is
esent, free-wall rupture, hemorrhagic conversion, or aortic
ssection should be considered. Anticoagulation should be
scontinued in the presence of a significant (1 cm) or
larging pericardial effusion.
.7. Thromboembolic and Bleeding
omplications
.7.1. Thromboembolic Complications
.7.1.1. ANTICOAGULATION: RECOMMENDATIONS¶
ASS I
Anticoagulant therapy with a vitamin K antagonist should be
provided to patients with STEMI and AF with CHADS2 score#
greater than or equal to 2, mechanical heart valves, venous
thromboembolism, or hypercoagulable disorder. (Level of Evi-
dence: C)
The duration of triple antithrombotic therapy with a vitamin K
antagonist, aspirin, and a P2Y12 receptor inhibitor should be
minimized to the extent possible to limit the risk of bleeding.**
(Level of Evidence: C)
ASS IIa
Anticoagulant therapy with a vitamin K antagonist is reason-
able for patients with STEMI and asymptomatic LV mural
thrombi. (Level of Evidence: C)
ASS IIb
Anticoagulant therapy may be considered for patients with
STEMI and anterior apical akinesis or dyskinesis. (Level of
Evidence: C)
Targeting vitamin K antagonist therapy to a lower international
normalized ratio (e.g., 2.0 to 2.5) might be considered in
patients with STEMI who are receiving DAPT. (Level of Evi-
dence: C)
revious recommendations for the use of vitamin K antago-
sts, either alone or in combination with low-dose aspirin,
r secondary prevention or for reducing the risk of systemic
romboembolism after STEMI, must be reconsidered in the
a of DAPT (4,48). The availability of several P2Y12
hese recommendations apply to patients who receive intracoronary stents during
I for STEMI. Among individuals with STEMI who do not receive an
tracoronary stent, the duration of DAPT beyond 14 days has not been studied
equately for patients who undergo balloon angioplasty alone, are treated with
rinolysis alone, or do not receive reperfusion therapy. In this subset of patients
th STEMI who do not receive an intracoronary stent, the threshold for initiation
oral anticoagulation for secondary prevention, either alone or in combination
th aspirin, may be lower, especially if a shorter duration (i.e., 14 days) of DAPT
planned (521).
#CHADS2 (Congestive heart failure, Hypertension, Age 75 years, Diabetes
ellitus, previous Stroke/transient ischemic attack [doubled risk weight]) score.
**Individual circumstances will vary and depend on the indications for triple
erapy and the type of stent placed during PCI. After this initial treatment period,
nsider therapy with a vitamin K antagonist plus a single antiplatelet agent. For
tients treated with fibrinolysis, consider triple therapy for 14 days, followed by a
amin K antagonist plus a single antiplatelet agent (522–525).
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ce on vitamin K antagonists as an alternative to aspirin for
pirin-allergic patients. A meta-analysis of RCTs comparing
arfarin plus aspirin to aspirin alone in patients with ACS
owed that in studies with an international normalized ratio
al of 2.0 to 3.0, combination therapy was associated with a
gnificant reduction in major adverse events at the expense
an increased risk of major bleeding (521). None of the
ials included patients treated with primary PCI or DAPT.
Triple therapy with a vitamin K antagonist, aspirin, and a
2Y12 receptor inhibitor should be restricted to specific
inical situations after STEMI in which the risk of systemic
venous thromboembolism or stent thrombosis is consid-
ed to exceed that of bleeding. Patient preferences and
lues should be taken into consideration, because individu-
s may weigh these outcomes differently. The novel oral
ticoagulants such as dabigatran have not been evaluated in
is context, and thus no recommendation for their use can be
ade. The duration of vitamin K antagonist therapy can be
mited to 3 months in patients with or at risk for LV
rombus (e.g., those with anteroapical akinesis or dyskine-
s), whereas the duration of DAPT could be predicated on
ent type or whether STEMI treatment included a stent
19,522,523). For patients undergoing primary PCI who
quire anticoagulation, avoidance of a DES is strongly
eferred. When triple therapy is used, an international
rmalized ratio targeted to a range of 2.0 to 2.5 might be
asonable, though prospective data are lacking. Use of
APT alone with aspirin and clopidogrel also might be
nsidered for patients with STEMI who have AF and low to
termediate CHADS2 scores (0 to 1), with reconsideration of
e indications for anticoagulation over time (296,522).
The incidence of venous thromboembolic events after
TEMI has declined significantly (526), though patients with
F or on prolonged bed rest remain at risk (527). The
proach to the prevention and treatment of venous throm-
embolic disease during hospitalization, with both pharma-
logical and mechanical measures, is similar to that for other
itically ill patients (528).
.7.1.2. HEPARIN-INDUCED THROMBOCYTOPENIA
IT, with or without associated thrombosis, can infrequently
mplicate the course of patients with ACS (529), particu-
rly patients who previously have been exposed to heparin or
ho receive heparin over several hospital days. From 1% to
of all patients receiving heparin will develop HIT, and of
gure 4. Adjusted risk of nonfatal and fatal bleeding in patients tr
st MI. Compared with aspirin alone, triple therapy is associated w
dicates confidence interval; HR, hazard ratio; and MI, myocardiaese, 25% to 50% will develop thrombotic complications. In Ge CATCH (Complications After Thrombocytopenia Caused
Heparin) registry (530,531), thrombocytopenia was com-
on among those who received heparin for 96 hours
6.4%) and was associated with a significantly increased risk
death, MI, or HF. Recognition of HIT frequently was
layed, and treatment often did not include a direct thrombin
hibitor. Data on the use of direct thrombin inhibitors in
tients with STEMI who develop HIT are limited (532,533).
or patients with STEMI and HIT who require stenting,
valirudin would be the preferred anticoagulant. Manage-
ent of patients with HIT who require urgent CABG can be
ore difficult (534).
.7.2. Bleeding Complications
espite variable definitions for major and minor bleeding
ed in clinical trials, bleeding that complicates the course of
ACS, including STEMI, is independently associated with
current MI, stroke, death, longer hospital stay, and in-
eased cost. The risk of death increases as a function of the
verity of bleeding, independent of the success or failure of
perfusion therapy. In a pooled analysis from 4 ACS trials,
e adjusted hazard ratio for death within 30 days ranged from
6 with mild bleeding to 10.6 with severe bleeding (535).
ost bleeding is procedure related, although gastrointestinal
d intracerebral bleeding may be more life threatening.
actors likely to contribute to adverse outcomes with ACS-
lated bleeding include patient comorbidities (536,537),
scontinuation of antiplatelet or anticoagulant therapy in
sponse to bleeding (536,538), and blood transfusion
39,540). Additional considerations include types of anti-
atelet or anticoagulant agent at time of PCI (248,541,542),
mber of antithrombotic agents used (533), dosing (543),
ration of therapy, crossover from low-molecular-weight
parin to UFH, HF or shock, diabetes mellitus, peripheral
tery disease, and prior warfarin use. If triple antithrombotic
erapy is required after discharge, the risk of bleeding
creases (Figure 4) (533).
Risk factors for bleeding in patients with ACS have been
entified from several clinical trials (535,544–546) (Table 13).
redictive models for major bleeding in patients with ACS and
patients undergoing PCI have been reported from the NCDR
CTION Registry–GWTG (547,548). An analysis from the
CTION Registry–GWTG suggests that the CRUSADE bleed-
g risk score, developed in patients with non–ST-elevation MI,
ay be extended to the STEMI population (549). Major bleed-
g occurred in 2.8% of 40,000 patients with acute MI in the
with aspirin, clopidogrel, and/or vitamin K antagonists after
3- to 4-fold increased risk of fatal and nonfatal bleeding. CI
tion. Adapted with permission from Sørensen et al. (533).eated
ith aRACE Registry (536). Patients who experienced a major
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ose who did not bleed (20.9% versus 5.6%; p0.001), even
ter adjustment for several relevant demographic and clinical
riables. One in 5 patients with a major bleed did not survive to
spital discharge; these patients accounted for 10% of all
spital deaths and were older, more severely ill, and more
ely to undergo invasive procedures. In ExTRACT-TIMI 25
noxaparin and Thrombolysis Reperfusion for Acute Myocar-
al Infarction Treatment—Thrombolysis In Myocardial Infarc-
n 25), high 30-day mortality rates after major bleeding in
tients with STEMI treated with fibrinolysis and either unfrac-
nated or low-molecular-weight heparin were driven largely by
e very poor prognosis associated with ICH (65% mortality
te) (537). The overall incidence of ICH in this study was 0.6%
32). The relationship between non-ICH bleeding and death in
th ExTRACT-TIMI 25 and TRITON-TIMI 38 may have been
nfounded by patient attributes, severity of illness, and treat-
ent protocols (537,550). To minimize the risk of bleeding
mplications, an assessment of patient, procedural, and phar-
acological risk factors should be performed at time of presen-
tion with STEMI and continuously thereafter. As an example,
longer time to PCI may be justifiable if the risk of hemorrhage
ith fibrinolysis is considered prohibitive.
Evidence suggests that although anemia is a risk factor for
eeding, the threshold for transfusion should be high (551).
bsent ongoing ischemia, transfusion should be avoided
less the hemoglobin level is 8 mg/dL. The optimal
moglobin level in the transfused patient is not known, but
e number of units provided should be minimized (539,552).
.7.2.1. TREATMENT OF ICH
lder age, female sex, low body weight (70 kg [female] and
80 kg [male]), prior stroke, and hypertension on presenta-
on (with a graded increase beginning at160 to 170 mm Hg
stolic) are the major risk factors for ICH. Once ICH is
cognized, all antiplatelet and anticoagulant therapy
ould be stopped. Brain imaging with emergency neuro-
ble 13. Selected Risk Factors for Bleeding in
tients With ACS
vanced age (75 y)
male sex
or shock
abetes mellitus
dy size
story of GI bleeding
esentation with STEMI or NSTEMI (vs UA)
vere renal dysfunction (CrCl 30 mL/min)
evated white blood cell count
emia
e of fibrinolytic therapy
vasive strategy
appropriate dosing of antithrombotic medications
ronic oral anticoagulant therapy
ACS indicates acute coronary syndrome; CrCl, creatinine clearance; GI,
strointestinal; HF, heart failure; NSTEMI, non–ST-elevation myocardial in-
rction; STEMI, ST-elevation myocardial infarction; and UA, unstable angina
53,554,543,547).gical and neurosurgical consultation is required. Consid- deation can be given to the use of protamine, fresh frozen
asma, prothrombin complex concentrates, activated fac-
r VII (555), and platelets as indicated. Resumption and
ming of anticoagulant and/or antiplatelet therapy after
H should be individualized and guided by neurosurgical
nsultation (556).
.7.2.2. VASCULAR ACCESS SITE BLEEDING
ascular access site bleeding is the most common type of
eeding after STEMI, particularly after PCI. PCI trials have
entified female sex, advanced age, renal insufficiency,
emia, IABP, use of GP IIb/IIIa antagonists, and low-
olecular-weight heparin within 48 hours of PCI as risk
ctors for femoral access site bleeding (557). Larger sheath
ze, postprocedural heparin use, higher activated clotting
mes, and late postprocedural sheath removal increases the
sk of access site bleeding and should be avoided. Radial
tery access may decrease bleeding complications and
ould be considered whenever feasible (558), but procedural
ccess with this technique is dependent on operator experi-
ce (559,560). Among patients with STEMI in the RIVAL
adial Versus Femoral Access for Coronary Angiography
d Intervention in Patients with Acute Coronary Syndromes)
ial, radial artery access appeared to reduce the rate of the
imary composite outcome (death, MI, stroke, non–CABG-
lated major bleeding) and the individual secondary out-
mes of death, MI, stroke, and overall mortality. However,
tes of major bleeding were not lower with radial versus
moral access in patients with STEMI, though rates of major
scular complications were significantly reduced (561).
lthough arterial closure devices have been associated with
creased femoral access site bleeding, more rapid hemosta-
s, and shorter duration of bed rest (251,562,563), their
utine use cannot be advocated specifically to reduce vas-
lar complications after PCI, given the lack of robust,
rectionally consistent data on their efficacy and safety
mpared with manual compression (564–566). Retroperito-
al bleeding should be suspected when the following are
en: unheralded intraprocedural or postprocedural hypoten-
on and bradycardia (or tachycardia), high vascular puncture
te, and an otherwise unexplained decrease in hemoglobin.
rompt computed tomographic imaging of the abdomen and
lvis may be helpful. Conservative management usually
ffices, but early vascular interventional or surgical consul-
tion should be obtained (219).
.8. Acute Kidney Injury
he risk of renal failure with STEMI relates to a host of
ctors, including patient age, prehospital renal function,
edications, contrast volume, and hemodynamic status.
ontrast-induced nephropathy after angiography and inter-
ntion for STEMI is always a risk, and attention to minimi-
tion of contrast volume and optimal hydration is required
19).
.9. Hyperglycemia
here is a U-shaped relationship between glucose levels and
ath in STEMI and ACS (567). The mortality rate associated
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January 29, 2013:e78–140 2013 ACCF/AHA STEMI Guideline: Full Textith hypoglycemia appears to be as high as the mortality rate
sociated with hyperglycemia (568,569). Concern about
erly aggressive glycemic control in critically ill patients
as raised by the NICE-SUGAR (Normoglycemia in Inten-
ve Care Evaluation and Survival Using Glucose Algorithm
egulation) trial (570). In this study of medical and surgical
tensive care unit patients, tight glucose control (81 to 108
g/dL) compared to modest control (180 mg/dL) was
sociated with increased mortality rate (primarily from
rdiovascular causes) and more episodes of hypoglycemia.
lood glucose levels should be maintained below 180 mg/dL
possible while avoiding hypoglycemia. There is no estab-
shed role for glucose-insulin-potassium infusions in patients
ith STEMI (571–573).
0. Risk Assessment After STEMI
itial risk stratification should be performed early (Section 3)
ith the use of information available at the time of presen-
tion. However, risk assessment is a continuous process that
quires recalibration on the basis of data obtained during the
spital stay. Such data include the success of reperfusion
erapy, events that occur during the hospital course (such as
morrhagic complications), and the findings from noninva-
ve and invasive testing, particularly as they relate to the
sessment of LV systolic function. For example, in patients
eated with fibrinolytic therapy, clinical and ECG indicators
failed reperfusion identify individuals who should undergo
gent coronary angiography with intent to perform PCI
56). In addition, the emergence of HF or significant LV
stolic dysfunction is among the strongest predictors of
gher-mortality risk after STEMI.
Stable patients with a low risk of complications may be
ndidates for early discharge. Among patients with
TEMI managed with fibrinolysis, it has been suggested
at an uncomplicated course after 72 hours of hospital-
ation identifies a group with sufficiently low risk to
able discharge (574,575). Newby and colleagues calcu-
ted that extending the hospital stay of these patients by
other day would cost $105,629 per year of life saved.
owever, the duration of hospitalization in patients treated
ith reperfusion therapy may be determined by other
eds, such as patient education or titration of medications
optimum doses (576).
Physicians and patients must individualize strategies for risk
duction, using lifestyle interventions, disease-modifying pharma-
logical therapies, and additional coronary revascularization
hen indicated. All patients with STEMI are considered to be
sufficiently high risk to merit interventions for secondary
evention, including the use of cardiac rehabilitation, aspi-
n, lipid-lowering therapy, beta blockers, and ACE inhibitors
hen indicated (257). Additional risk assessment should be
ed to guide decisions about performance of coronary
giography in patients who did not undergo an invasive
aluation as part of their initial treatment strategy and to
ide consideration of interventions to reduce the risk of SCD
e to arrhythmia. pr0.1. Use of Noninvasive Testing for
chemia Before Discharge:
ecommendations
ASS I
Noninvasive testing for ischemia should be performed before
discharge to assess the presence and extent of inducible
ischemia in patients with STEMI who have not had coronary
angiography and do not have high-risk clinical features for
which coronary angiography would be warranted (577–579).
(Level of Evidence: B)
ASS IIb
Noninvasive testing for ischemia might be considered before
discharge to evaluate the functional significance of a nonin-
farct artery stenosis previously identified at angiography.
(Level of Evidence: C)
Noninvasive testing for ischemia might be considered before
discharge to guide the postdischarge exercise prescription.
(Level of Evidence: C)
oninvasive testing for ischemia provides valuable informa-
on about the presence of residual ischemia in patients who
ve not undergone cardiac catheterization during initial
anagement of STEMI and may be useful in assessing the
nctional significance of a noninfarct artery stenosis identi-
ed at angiography. In the latter instance, stress imaging to
calize ischemia would be appropriate (580,581). Exercise
sting early after STEMI may also be performed to 1) assess
nctional capacity and the ability to perform tasks at home
d at work, 2) evaluate the efficacy of medical therapy, and
assess the risk of a subsequent cardiac event. Symptom-
mited exercise testing is a key feature of the intake evalu-
ion for enrollment in a program of cardiac rehabilitation2
eeks after discharge (582).
Low-level exercise testing after MI appears to be safe if
tients have undergone in-hospital cardiac rehabilitation,
cluding low-level exercise; have had no symptoms of
gina or HF; and have a stable baseline ECG 48 to 72 hours
fore the test (583). Two different protocols have been used
r early post-MI exercise testing: the traditional submaximal
ercise test (done at 3 to 5 days in patients without
mplications) or a symptom-limited exercise test (done at 5
ys or later) without stopping at a prespecified target heart
te or metabolic equivalent level. RCTs of early exercise
sting after PCI have excluded patients with recent MI (584).
imited data exist on the safety of early symptom-limited
ercise testing after MI; therefore, clinical judgment must be
ed (585). Pharmacological stress myocardial perfusion
aging has been shown to have predictive value for postin-
rction cardiac events and is useful and safe in patients who
e unable to exercise (586). The optimum timing for pro-
cative testing for ischemia after STEMI remains unre-
lved. It is argued that a predischarge exercise test may
ovide psychological benefit to the patient and will permit
tection of profound ischemia or other indicators of high
sk that could be associated with postdischarge cardiac
ents that might occur before a symptom-limited stress test
heduled weeks later (585). A predischarge study also
ovides parameters for exercise prescription in the first few
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ation. On the other hand, deferring exercise testing until
proximately 3 weeks after STEMI in clinically low-risk
tients appears safe and reasonable and enables more opti-
al assessment of functional capacity. It is the consensus of
e writing committee that patients without complications
ho have not undergone coronary angiography and who
ight be potential candidates for revascularization should
dergo provocative testing before hospital discharge. In
tients with noninfarct artery disease who have undergone
ccessful PCI of the infarct artery and have an uncompli-
ted course, it is reasonable to proceed with discharge and
ans for close clinical follow-up with stress imaging within
to 6 weeks.
0.2. Assessment of LV Function:
ecommendation
ASS I
LVEF should be measured in all patients with STEMI. (Level of
Evidence: C)
V function is one of the strongest predictors of survival in
tients with STEMI. LV function most commonly is evalu-
ed with contrast ventriculography at the time of cardiac
theterization or with transthoracic echocardiography on day
or 3. Echocardiography is the most frequently used imaging
odality to evaluate regional and global LV function after
TEMI and can help characterize any associated mechanical
mplications when they are clinically suspected. Because of
e dynamic nature of LV functional recovery after STEMI,
inicians should consider the timing of the imaging study
lative to the index event. In patients with significant LV
stolic dysfunction revealed during the initial hospitaliza-
on, LV function should be reevaluated 40 days later,
pecially to address the potential need for ICD therapy
ter allowance for recovery from myocardial stunning
96,587,588).
0.3. Assessment of Risk for SCD:
ecommendation
ASS I
Patients with an initially reduced LVEF who are possible
candidates for ICD therapy should undergo reevaluation of
LVEF 40 or more days after discharge (496,587–589). (Level of
Evidence: B)
he timing and character of ventricular arrhythmias and
sidual LV systolic function are the strongest predictors of
CD risk after STEMI. Management considerations for
tients with ventricular arrhythmias during the hospital
ase are reviewed in Section 9.5. Hospital survivors with an
itially reduced LVEF (0.40) who do not merit ICD
erapy before discharge should undergo reassessment of LV
nction 40 days later to determine their eligibility for ICD
erapy. The recommended delay to ICD therapy in this
tting stems from the results of DINAMIT (Defibrillator in
cute Myocardial Infarction Trial), in which defibrillator
plantation 6 to 40 days after MI in patients with EF 0.35
d impaired cardiac autonomic function was not shown to paduce overall cardiac death risk. The observed reduction in
rhythmic deaths was offset by a relative increase in the
mbers of nonarrhythmic deaths (587). The IRIS (Immedi-
e Risk Stratification Improves Survival) trial (588) also
owed that early ICD therapy in patients with LVEF 0.40
d a high heart rate, nonsustained VT regardless of LVEF, or
th did not result in improved survival. The utility of a
earable cardioverter-defibrillator in high-risk patients dur-
g the first 4 to 6 weeks after STEMI is under investigation
ttp://clinicaltrials.gov/ct2/show/NCT00628966).
The indications for ICD therapy40 days after STEMI are
sed on LVEF and New York Heart Association class, as
rived from the results of the landmark MADIT 2 (Multi-
nter Automatic Defibrillator Implantation Trial 2) and
CDHeFT (Sudden Cardiac Death in Heart Failure) trials
96,589–591). If LVEF remains 0.35 and the patient has
ew York Heart Association class II or III HF symptoms, or
the LVEF is 0.30 independent of symptoms, then ICD
plantation is recommended (496). Indications for cardiac
synchronization therapy in the late, convalescent phase of
TEMI include residual LV function, New York Heart Associ-
ion class, QRS duration, and LBBB morphology (592).
In addition to determination of LVEF, several other noninva-
ve strategies have been proposed to identify patients at high
sk for arrhythmic events after STEMI, such as signal-averaged
high-resolution ECG, heart rate variability, baroreflex sensi-
ity, and T-wave alternans (591). These strategies have not
en adopted widely because of their limited performance charac-
ristics and are not recommended for routine use.
1. Posthospitalization Plan of Care
1.1. Posthospitalization Plan of Care:
ecommendations
ASS I
Posthospital systems of care designed to prevent hospital
readmissions should be used to facilitate the transition to
effective, coordinated outpatient care for all patients with
STEMI (593–597). (Level of Evidence: B)
Exercise-based cardiac rehabilitation/secondary prevention
programs are recommended for patients with STEMI (598–
601). (Level of Evidence: B)
A clear, detailed, and evidence-based plan of care that pro-
motes medication adherence, timely follow-up with the health-
care team, appropriate dietary and physical activities, and
compliance with interventions for secondary prevention should
be provided to patients with STEMI. (Level of Evidence: C)
Encouragement and advice to stop smoking and to avoid
secondhand smoke should be provided to patients with STEMI
(602–605). (Level of Evidence: A)
1.1.1. The Plan of Care for Patients With STEMI
ducation of patients with STEMI and their families is
itical and often challenging, especially when transitions of
re occur. Failure to understand and comply with a plan of
re may account for the high rate of STEMI rehospitaliza-
on rates seen in the United States (19,606). One key
tervention to ensure effective coordination is to provide to
tients and caregivers, during the hospital stay, a compre-
he
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mpliance with recommended evidence-based therapies
07–609). The posthospitalization plan of care for patients
ith STEMI should address in detail several complex issues,
cluding medication adherence and titration, timely follow-
ble 14. Plan of Care for Patients With STEMI
Plan of Care
edications
Antithrombotic therapies
Beta blockers
ACE inhibitors/ARBs/aldosterone antagonists
Statins
Sectio
Sectio
Sectio
Sectio
ESC S
ACC/A
ysical activity/cardiac rehabilitation
Physical Activity
Cardiorespiratory fitness (MET capacity)
AHA/A
AACV
sk factor modification/lifestyle interventions
Smoking cessation
AHA/A
ACCP
Diet/nutrition AHA/A
anagement of comorbidities
Overweight/obesity
Lipids
Hypertension
Diabetes
HF
Arrhythmia/arrhythmia risk
AHA/A
AHA/A
NHLB
AHA/A
ACC/A
ACC/A
ychosocial factors
Sexual activity
Gender-specific issues
Depression, stress, and anxiety
Alcohol use
Culturally sensitive issues
AHA S
Cardio
AHA S
AHA/A
ovider follow-up
Cardiologist
Primary care provider
Advanced practice nurse/physician assistant
Other relevant medical specialists
Electronic personal health records
Influenza vaccination
H2H Q
Cente
tient/family education
Plan of care for acute MI
Recognizing symptoms of MI
Activating EMS, signs and symptoms for urgent vs
emergency evaluations
CPR training for family members
Risk assessment & prognosis
Advanced directives
Social networks/social isolation
AHA C
cioeconomic factors
Access to health insurance coverage
Access to healthcare providers
Disability
Social services
Community services
http:/
AACVPR indicates American Association of Cardiovascular and Pulmonary Reha
undation; ACCP, American College of Chest Physicians; ACE, angiotensin-co
erican Heart Association; ARB, angiotensin receptor blocker; CPR, cardiopulm
abetes mellitus; EMS, emergency medical services; ESC, European Society of
erica; HRS, Heart Rhythm Society; JNC, Joint National Committee; MET, metstitute; SIHD, stable ischemic heart disease; and STEMI, ST-elevation myocardial infa, dietary interventions, physical and sexual activities,
rdiac rehabilitation, compliance with interventions for sec-
dary prevention (Table 14), and reassessment of arrhyth-
ic and HF risks. In addition, providers should pay close
tention to psychosocial and socioeconomic issues, including
Resources/References
5.1, 6.4
uideline (48)
2 SIHD Guideline (614)
1 Update: Secondary Prevention and Risk Reduction Therapy (249)
/AHA 2010 Update: Performance Measures on Cardiac Rehabilitation (616)
1 Update: Secondary Prevention and Risk Reduction Therapy (249)
o Cessation Toolkit (615)
1 Update: Secondary Prevention and Risk Reduction Therapy (249)
1 Update: Secondary Prevention and Risk Reduction Therapy (249)
1 Update: Secondary Prevention and Risk Reduction Therapy (249)
al Hypertension Education Program (JNC VII) (617)
Prevention in DM Patients (618)
A HF Guideline (619)
DBT & AF Guidelines (496,501)
Statement on Sexual Activity and Cardiovascular Disease (627a)
r Disease Prevention in Women Guidelines (620)
Statement on Depression (621)
1 Update: Secondary Prevention and Risk Reduction Therapy (249)
nitiative http://www.h2hquality.org
isease Control Adult Vaccinations (622)
eline (201)
alityforum.org/Topics/Care_Coordination.Aspx
; ACC, American College of Cardiology; ACCF, American College of Cardiology
enzyme; ADA, American Diabetes Association; AF, atrial fibrillation; AHA,
esuscitation; CVD, cardiovascular disease; DBT, device-based therapy; DM,
gy; H2H, hospital-to-home; HF, heart failure; HFSA, Heart Failure Society of
quivalent; MI, myocardial infarction; NHLBI, National Heart, Lung, and Bloodns 4.4,
n 8.1
n 8.2
n 8.3
TEMI G
HA 201
CC 201
PR/ACCF
CC 201
Tobacc
CC 201
CC 201
CC 201
I Nation
DA CVD
HA/HFS
HA/HRS
cientific
vascula
cientific
CC 201
uality I
rs for D
PR Guid
/www.qu
bilitation
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1.1.2. Smoking Cessation
he value of smoking cessation for the secondary prevention
cardiovascular disease has been demonstrated in several
ospective observational studies. A meta-analysis of cohort
udies in patients after acute MI showed that smoking
ssation reduced the subsequent cardiovascular mortality
te by nearly 50% (602), ranking it among the most powerful
condary prevention strategies (603). The SAVE (Sleep
pnea Cardiovascular Endpoints) study investigators re-
rted that in selected patients with LV systolic dysfunction
ter MI, smoking cessation, compared with continued smok-
g, is associated with a 40% lower hazard of all-cause
ortality and a 30% lower hazard of death, recurrent MI, or
F hospitalization (605).
Reasonable evidence from RCTs indicates that counseling
spitalized smokers after acute MI increases smoking ces-
tion rates, provided that the initial contact during the
spital stay is followed by repeated contacts, usually by
lephone, for 3 months after discharge (603,604). Simi-
rly, the odds of smoking cessation are greater among
tients who receive discharge recommendations for cardiac
habilitation (604). Patients with depressive symptoms dur-
g the MI hospitalization and early convalescence are less
kely to quit smoking and may require more intensive
eatment to achieve cessation (603,604). Counseling should
provided to the patient and family, along with pharmaco-
gical therapy as deemed safe, and access to formal
oking-cessation programs should be facilitated.
1.1.3. Cardiac Rehabilitation
he objectives of contemporary exercise-based cardiac reha-
litation are to increase functional capacity, decrease or
leviate anginal symptoms, reduce disability, improve qual-
y of life, modify coronary risk factors, and reduce morbidity
d mortality rates (598,613,614). Core components include
tient assessment; ongoing medical surveillance; nutritional
unseling; BP, lipid, and diabetes mellitus management;
oking cessation; psychosocial counseling; physical activity
unseling; exercise training; and pharmacological treatment,
appropriate (614).
Among 601,099 U.S. Medicare beneficiaries who were
spitalized for coronary conditions or revascularization
ocedures, mortality rates were 21% to 34% lower among
rticipants in cardiac rehabilitation programs than among
nparticipants (599). It has been suggested that contempo-
ry reperfusion and cardioprotective drug therapies may
minish the impact of adjunctive exercise-based cardiac
habilitation programs on post-MI survival rate. Taylor et al.
00) conducted a systematic review and meta-analysis of
CTs of cardiac rehabilitation with 6 months of follow-up.
he study population included 8,940 patients, a greater
mber were women (20% of the cohort), patients 65 years
age, and individuals who had undergone revascularization
ocedures. Compared with usual care, cardiac rehabilitation
as associated with a reduction in total and cardiac mortality
tes of 20% and 26%, respectively. Subgroup analyses
owed that the decreased mortality rates did not differ across (6veral patient subsets, between programs limited to exercise
d those providing more comprehensive secondary interven-
ons, or between pre- and post-1995 studies, which suggests
at the mortality benefits of cardiac rehabilitation persist in
e modern era. However, despite these impressive outcomes,
rdiac rehabilitation services remain vastly underutilized
82,615).
1.1.4. Systems of Care to Promote Care
oordination
eaningful evidence has facilitated a much better under-
anding of the systems changes necessary to achieve safer
re (616). This includes the adoption by all U.S. hospitals of
standardized set of “Safe Practices” endorsed by the
ational Quality Forum (617), which overlap in many ways
ith the National Patient Safety Goals espoused by The Joint
ommission (618). Examples of patient safety standards that
ould be ensured for all patients discharged after STEMI
clude improved communication among physicians, nurses,
d pharmacists; medication reconciliation; careful transi-
ons between care settings; and consistent documentation.
he National Quality Forum also has endorsed a set of
tient-centered “Preferred Practices for Care Coordination,”
19) which detail comprehensive specifications that are
cessary to achieve the goals of successful care coordination
r patients and their families. Systems of care designed to
pport patients with STEMI and other cardiac diseases can
sult in significant improvement in patient outcomes. To
ovide the interventions and services listed in Table 14,
propriate resources must be applied to ensure that all
tients with STEMI have full access to evidence-based
erapies and follow-up care. There is a growing emphasis on
nalizing hospitals for avoidable hospital readmissions.
ence, it is imperative for health systems to work in partner-
ip with physicians, nurses, pharmacists, communities, pay-
s, and public agencies to support the interventions that
hieve such comprehensive care.
Patient characteristics may be important predictors of
admission after MI; however, only a few variables have
en identified consistently (620,621). From a policy per-
ective, a validated risk-standardized model that uses read-
ission rates to profile hospitals is not currently available.
2. Unresolved Issues and Future
esearch Directions
he writing committee has identified several areas pertaining
the management of patients with STEMI that deserve
rther research. Although the observations from the Swedish
TEMI registry showing an association between the in-
eased use of evidence-based treatments and declining mor-
lity rates after STEMI are encouraging (18), additional
forts to improve patient outcomes are needed. There is
idespread acknowledgment that progress in closing existing
owledge and performance gaps will require contributions
om a wide range of investigators, dedicated clinicians,
spital and health plan administrators, regional emergency
sponse systems, and both government and private payers
31).
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elay times from onset of symptoms to activation of STEMI
re pathways remain unacceptably long (51,631). Multicul-
ral efforts to educate, reassure, and motivate at-risk patients
d their families are needed. Comparable efforts to improve
herence and attention to healthy lifestyle behaviors as the
rnerstones of secondary prevention are required at time of
scharge and as an integral feature of cardiac rehabilitation
ograms.
2.2. Regional Systems of Care
he adoption of regional systems of care for patients with
TEMI across diverse geographical areas has proved chal-
nging, and inappropriate delays to initiation of reperfusion
erapy are common (632). As previously emphasized, atten-
on should be focused on reducing the total ischemic time,
om onset of symptoms to successful reperfusion. Several
ctors in addition to patient activation of EMS contribute to
lays, not all of which can be reconciled. Areas for contin-
d research include prehospital EMS protocols, the approach
out-of-hospital cardiac arrest, triage and transfer algo-
thms, rapid availability of expert PCI services, and further
finement of the clinical and time-related factors that should
ompt earlier use of fibrinolytic therapy coupled with im-
ediate transfer for PCI (129,633–635). The lack of corre-
tion between shorter D2B times and reduced mortality
ould drive further efforts to improve all aspects of STEMI
re (636). Regional systems should track, analyze, and
port all STEMI and out-of-hospital cardiac arrest events as
rt of an ongoing process-improvement program.
2.3. Transfer and Management of
on–High-Risk Patients After
dministration of Fibrinolytic Therapy
he indications for and timing of transfer for angiography
ith a view toward revascularization of non– high-risk
tients after successful fibrinolysis are still debated.
lthough there has been increasing activation of this
thway, the evidence base for its justification is still
mited (358,360,365).
2.4. Antithrombotic Therapy
he optimum choice of P2Y12 receptor inhibitor and antico-
ulant agents for patients with STEMI can be challenging.
dividual genetic variability in drug absorption, metabolism,
d effectiveness has been highlighted by the experience with
opidogrel in patients with ACS (285,637). The risks of
eeding also may vary across racial and ethnic groups (12).
he roles of platelet function testing and genetic screening for
opidogrel metabolism in the acute phase of STEMI care are
certain (289), especially with the availability of alternative
2Y12 receptor inhibitors. More information specific to pa-
ents with STEMI is needed with regard to the use of
asugrel, ticagrelor, novel factor Xa and IIa antagonists, and
atelet protease–activated receptor 1 antagonists (638,639).
he efficacy and safety of combination (“triple”) antithrom-
tic therapy must be addressed continuously (525,537),hile less hazardous approaches are tested. Bleeding ratesith radial versus femoral artery access for PCI warrant
rther prospective study (561).
2.5. Reperfusion Injury
side from manual aspiration thrombectomy, efforts to coun-
ract the “no-reflow” phenomenon and to limit myocardial
perfusion injury have had limited success. The value of
piration thrombectomy in patients with anterior STEMI has
en questioned (223). Remote ischemic preconditioning has
gendered little enthusiasm. Trials evaluating the use of
tithrombotic and vasodilator agents have been disappoint-
g. New biological, pharmacological, and mechanical strat-
ies should be investigated to facilitate prompt recovery of
ssue-level perfusion (220,640–642,644). In addition, high-
se statin pretreatment before primary or delayed PCI for
TEMI requires further study (645).
2.6. Approach to Noninfarct Artery Disease
here is great variability in the evaluation and management
nonculprit coronary artery disease in stable patients with-
t HF or shock, both at the time of primary PCI and later
ring the hospital course. Physiological assessment of lesion
gnificance is often not performed, and the decision to
oceed with PCI is made on anatomic grounds. More work
needed to clarify the indications for and timing of nonin-
rct artery revascularization (218,224,228,229).
2.7. Prevention of SCD
rediction of electrical vulnerability and SCD risk after
TEMI is fraught with imprecision. Treatment decisions rely
most exclusively on parameters of LV systolic function.
ptimal therapy for at-risk individuals in the time window
tween discharge and 40 days, the time point after which
D therapy is currently recommended, has not been estab-
shed. Improved prediction rules and validated treatment
commendations are urgently needed (646).
2.8. Prevention of HF
uch progress has been made to limit LV remodeling,
ough there remains substantial room for improvement,
ginning with the timeliness of reperfusion and initiation of
CE inhibitor/ARB therapy (627). The superimposition of
chemic mitral regurgitation adds further to the risks of HF
d death. Continued exploration of the roles of cell- and
ne-based therapies after STEMI is encouraged (647–656).
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E  angiotensin-converting enzyme
S  acute coronary syndrome
 atrial fibrillation
B  angiotensin receptor blocker
 atrioventricular
S  bare-metal stent
 blood pressure
BG  coronary artery bypass graft
X-2  cyclooxygenase-II enzyme
R  cardiopulmonary resuscitation
Cl  creatinine clearance
B  door-to-balloon (device)
PT  dual antiplatelet therapy
S  drug-eluting stent
G  electrocardiogram/electrocardiographic
 emergency department
 ejection fraction
S  emergency medical services
C  first medical contact
 glycoprotein
 heart failure
T  heparin-induced thrombocytopenia
BP  intra-aortic balloon counterpulsation
D  implantable cardioverter-defibrillator
H  intracranial hemorrhage
BB  left bundle-branch block
L  low-density lipoprotein
 left ventricular
EF  left ventricular ejection fraction
I  myocardial infarction
MI  National Registry of Myocardial Infarction
I  percutaneous coronary intervention
T  randomized controlled trial
 right ventricular
D  sudden cardiac death
EMI  ST-elevation myocardial infarction
MI  Thrombolysis In Myocardial Infarction
H  unfractionated heparin
 ventricular fibrillation
 ventricular tachycardia
